




APPENDIX

0 ACTACAATAA TTCATGTATA AAACCTAAGGG CGTAAACCAGG ATCCGGTTGAA CCQAAACCAGG TTAGTATAAAA AGCAGACATT TTATGCACCA AAAGAGAAGT
100 GCAATGTTTC AGGACCACCA GGAGCCGACC AGAAAGTTAC CACAGTTATG CACAGAGCTG CAACAACACTA TACATGATAT AATATTAGAA TGTTGTAAGT
200 GCAAGCAACA GTTACTGCCA CGTGGAGTAT ATGACTTTTC TTTTCGGGAT TTATGCATAG TATATAGAGA TGGGAATCCA TATGCTGTAT TATGCTGTAAGT
300 TTTAAGT TTT TATTCTAAAA TTAGTGAFTA TAGACATTAT TGTITATAGTY TGTATGGAAAC AACATTAGAAA CAGCAATACA ACAAAACCGTT GTGTGTTTGG
400 TTAATTAGGT GTATTAACCTG TCAAAAAGCCA CTGTGTCTGT AAGAAAAAGCA AAGACATCTG GACAAAAAGC AAAGATTCCA TAATATAAGG GGTTCGGTGA
500 CCGTGTGAGT TATGCTCTGT TCGACATCAT CAAGAACACG TAGAGAAAAC CAGCTGTAAT CATGCATGGA GATACACCTA CATTCGATGA ATATATGTTA
600 GATTTTGCAC CAGAGACAAC TGATCTCTAC TGTITAGACC AATTAATGGA CAGCTGAGAG GAGGAGGATG AATATAGATGG TCCAGCTGGA CAAGCAGAAC
700 CCGACAGAGC CCATTACAAT ATTTGAACCT TTTGTTGCAG GTGTGACTCT ACCTTCGGT TGTCTGAGA ACCATAATC TGTCTGTACA AATATAGATGG
800 AGCCCTGTTA ATGGGCACAC TAGGAATTGT GTGCCCATC GTCTGTAGTG AAAAAAAGC AAGGAGTATG TATATAGAGA TGGGAATCCA TATGCTGTAT
900 AGGATTTGGT AGATTTTATA CTAAATGATA ATGATTTATT AACACAGCCA GAARACAGAGA CAGCACAATG GTTGTITACT GCACAGGAGT CAACAACACA
1000 AAGATTTGGT TAAAAGSAAA GTATTTGGTA TCCACCTTAG TGAATTTAGT GGATGTGTAG ACAATAATAT TAGTCTTAGA TTAAGAGCTA
1100 TAGAGATGCA GTACAGGTTC TAAAAGSAAA GTATTTGGTA TCCACCTTAG TGAATTTAGT GGATGTGTAG ACAATAATAT TAGTCTTAGA TTAAGAGCTA
1200 TATGTTAGCA AAAACAAGT AGAGCTSCAA AAGSAGATAT ATTTGAAAGC GAAGCAGCGG GGTATGCGAA TACTGAAGTG GAAACTCAGC AGATCTTACA
1300 GGTAGAAAGG CCCCATGAGA CTGAAAACCC ATGTAGTCAG TATAGTGGTG TATAGTGGTG TATAGTGGTG TATAGTGGTG TATAGTGGTG TATAGTGGTG
1400 GTTAGTGAAA GACACACTAT ATGCCAACA CCACTTACAA ATATTTAAA GTACTAAAA ACTAGTAAAG CAAAGGCCAG AATGTTAGCA AAATTTAAG
1500 AGTTATACGG GGTGAGTTT TCGAATTAG TAAGCCATT TAAGSAGATAT ATTTGAAAGC GAAGCAGCGG GGTATGCGAA TACTGAAGTG GAAACTCAGC
1600 TATAGCTGAC AGTATAAAAA CACTATTACA ACAATATTGT TTATTTTAA ACATTCAAAG TTTAGCATGT TCAATGAGT TCAATGAGT TCGTTGCTCT
1700 AGATAAATAT GTGGAAAAA TAGAGAAAAA ATTGAAAAAT TCGTCTCAA ACTATTGT GTGTCTCAA TGTGTATGAT GTATAGAGCT CAAAATGGT
1800 TAGTACAGC AGCAGCATA TATTGGTATA AAACAGGATAT ATCAAATAT TCGTCTCAA ACTATTGT GTGTCTCAA TGTGTATGAT GTATAGAGCT
1900 ACACATAGT TTTAATGAT TAGTAAATGCA AGTGCCCTTC TAAAAGSAAA GTTACAGGCA AAATATTAGT TGTACAGGTA TATAGTGGTG TATAGTGGTG
2000 GCACAAATGG CAGACACTAA TAGTAATGCA AGTGCCCTTC TAAAAGSAAA GTTACAGGCA AAATATTAGT TGTACAGGTA TATAGTGGTG TATAGTGGTG
2100 AACGAGGACA AAAAAACAAA ATGAGTATGA GTCAAATGAT TTTAAGTGGT TTTAAGTGGT TTTAAGTGGT TTTAAGTGGT TTTAAGTGGT TTTAAGTGGT
2200 AACACAGGTA AATCATTTT TGTATGATTT TTTAAGTGGT TTTAAGTGGT TTTAAGTGGT TTTAAGTGGT TTTAAGTGGT TTTAAGTGGT TTTAAGTGGT
2300 TAGCAGATGC CAAAATAGGT ATGTTAGATG TTTAAGTGGT TTTAAGTGGT TTTAAGTGGT TTTAAGTGGT TTTAAGTGGT TTTAAGTGGT TTTAAGTGGT
2400 TATGGATGTA AAGCATAGAC ATGTTAGATG TTTAAGTGGT TTTAAGTGGT TTTAAGTGGT TTTAAGTGGT TTTAAGTGGT TTTAAGTGGT TTTAAGTGGT
2500 CATAAGTGGT TCGTGGTGGT CATTGGTACA ACTAAAATGC CCTCCATTAT TAATTACATC TAACATTAAT GCTGGTACAG ATTTAGTGGT GCCTTATTTA
2600 TCTCAAGGAC GTGGTCCAGA TTAAGTTTGC ACGAGGACGA GGACAAGGAA AACGATGGAG ACTCTTTGCC AACGTTAAA TGTGTCCAG CACAAAAATC
2700 YAACACATA TGAAAATAGT AGTACAGACC TACGTAACCA CACTTACAAG ACCTTACAAG TGAAGTGTAT TTAAGTGTAT TTAAGTGTAT TTAAGTGTAT
2800 GGGATTTAAA CATATTAAAC ACCAAGTGGT GCCAAGCAT GCCTGTATCA AGAATAAGC ATTACAAGCA ATTTAGCATGT TTAAGTGTAT TTAAGTGTAT
2900 TATAACTCAC AATATAGTAA TGAAAAAGTGG ACATTTACAAG ACCTTACAAG TGAAGTGTAT TTAAGTGTAT TTAAGTGTAT TTAAGTGTAT TTAAGTGTAT
3000 CAGTGGAAAT GCAGTTTGA TGGAGACATAT GCAATACAAT GCATATACAA AACTGGACAC ATATATATAT TTTGGAAGAA GCATCAGTAA CTGTGGTAGA
3100 GGGTCAAGTT GACTATTAGT GTTITATATTA TTTGATGAAA GGAATACGAA CATATTTTGT GCAGTTTAAA GATGATGCAG TATGATGCAG TTAAGTGTAT
3200 GTATGGGAAG TTTAGTGGGG TGGTCAAGTA ATATTATGTC CTACATCTGT GTTTAGCAGC AACGAGGAT CAACTTACAAG TTAAGTGTAT TTAAGTGTAT
3300 CAAACCCACC CCGCCGCAAG CATAACAAAG CCGTCCCTTC GGGCACCGTA GACAGTGGT GACAGTGGT GACAGTGGT GACAGTGGT GACAGTGGT
3400 AGTAAACATA CACCCATAGT ACATTTAAAA AGACTCAGTG GACAGTGGT GACAGTGGT GACAGTGGT GACAGTGGT GACAGTGGT GACAGTGGT
3500 CGTCTACATG GCAATGGACA GGACATAATG TAAACATAAA AAGTGCATTA GTTACACTTA GTTACACTTA GTTACACTTA GTTACACTTA GTTACACTTA
3600 AGTAAAAATA CAAAACACTA TACAGCTGTC TACAGCTGTC TACAGCTGTC TACAGCTGTC TACAGCTGTC TACAGCTGTC TACAGCTGTC TACAGCTGTC
3700 GCTTTGTGTT CTTTGTGTTG TCGTGGTGGT GTGTTTTATT GTATATATTA TATTTGTTTA TATACCATA TACTATTTT TCTTTTTTAT TTTGATATAT
3800 GATATGTGAC AATAAGTAAAT TGTACATAT AATTTGTTGA TACCATAAGT TACTATTTT TCTTTTTTAT TTTGATATAT AATTTTTTAT TTTGATATAT
3900 GTTTGTTTGT TTAATAACT GTTATTAGT AAACAATGCGA CACAACGTT CTGCAAAAAG CACAACAACT GCAACAAAT TACAATATGG AAGTATTTT TGAATTTTGT
4000 AAACAGCCAG TACATGCTCC ACCTGACATT ATACCTAAGG TTTGAAGAGG AACATTTGCT GAACAATAAT TACAATATGG AAGTATTTT TGAATTTTGT
4100 GTGGTTAGG AATTTGAAACA GGGTGGGTA CAGCGGGACG CACTGGGAT ATTCGATGG GAACAAGGCC TCCCACAGCT ACAGATAGAC TTTGCTGTT
4200 AAGACCCCTC TTTAAGTAGT ATCCCTGGG CCGTCTGTAT TTTCTTAGT GGAAGAAAAT GGAAGAAAAT GGAAGAAAAT GGAAGAAAAT GGAAGAAAAT
4300 GTACCTCCA TCCCACAGA TGTATCAGGA TTTAGTATTA CTACTTCAAC TGATACCACA CCTGCTATAT TAGATATTTA TAACTGGAGG GCATTTTACA
4400 CTACACATAA TAACTCCACT TCACTGACC CATCTGTATT GCAGCCTCCA ACACCTGCAG AAACCTGGAG GCATTTTACA TAACTGGAGG GCATTTTACA
4500 TACACATAAT TATGAAGAAA TTTCTATGGA TACATTTATT GTTAGCACA ACACCTGCAG AAACCTGGAG GCATTTTACA TAACTGGAGG GCATTTTACA
4600 GCACGCTAG GATTAATAG TCGCACACA CAACAGGTTA AAGTTGTAGA TAGTATGAT TAGTATGAT TAGTATGAT TAGTATGAT TAGTATGAT TAGTATGAT
4700 CATATGAAGG TATAGATGTT GATAATACAT TATATTTTTC TAGTATGAT TAGTATGAT TAGTATGAT TAGTATGAT TAGTATGAT TAGTATGAT TAGTATGAT
4800 ACATAGGCCA GCATTAACCT CTAGGGTAC CTAGGGTAC CTAGGGTAC CTAGGGTAC CTAGGGTAC CTAGGGTAC CTAGGGTAC CTAGGGTAC CTAGGGTAC
4900 AAGGTACATTT ATATTATGGA TTTAAGTACT TTTAAGTACT TTTAAGTACT TTTAAGTACT TTTAAGTACT TTTAAGTACT TTTAAGTACT TTTAAGTACT
5000 CCTCAGCTAC TTTATTAAT CAATACAAC AATTCCTTTT GGTGGTGCAT ACAATATTCC TTTAGTATCA TTTAGTATCA TTTAGTATCA TTTAGTATCA
5100 TTTACTAGGT TATATTCTGT TATAGTTCOA TATAGTTCOA TATAGTTCOA TATAGTTCOA TATAGTTCOA TATAGTTCOA TATAGTTCOA TATAGTTCOA
5200 GAAAACGAGC TAAAGTTTTC TAAAGTATGTT GCACGCACAA ACATATATTA TCAATGAGGA ACATCCAGAC TACTTGCAGT TGGAGTGGT TGGAGTGGT
5300 TAACCAATAA AAAATATTAG TAAAGTATGTT GCACGCACAA ACATATATTA TCAATGAGGA ACATCCAGAC TACTTGCAGT TGGAGTGGT TGGAGTGGT
5400 TCAATTTATA ATCCAGATAC ACAGCGGCTG GTTGGGCT GTGTAGGTT TGAAGTGGT TGAAGTGGT TGAAGTGGT TGAAGTGGT TGAAGTGGT TGAAGTGGT
5500 TATTAATAAA ATTTGATGAC ACAGAAAAATG CTAGTGCCTA TGCAGCAAA TGCAGCAAA TGCAGCAAA TGCAGCAAA TGCAGCAAA TGCAGCAAA
5600 ATGTGTTTAA ATGGTTGCA AACCCACTAT AGGGGAACAC TGGGGCAAGT GATCCCTGAT GATCCCTGAT GATCCCTGAT GATCCCTGAT GATCCCTGAT
5700 GFTTGTATTT ACACAGTTAT TCGAGTGGT GATATGTTTC TCGAGTGGT GATATGTTTC TCGAGTGGT GATATGTTTC TCGAGTGGT GATATGTTTC
5800 TCAATATATT CATTTATTTA ATAGSCTGG TACTGTTGGT GAAAATGTAC CAGAGGATTT ATACATTAAA GGCTCTGGGT CTACTGAAA TTAGGAGCT
5900 GCAATTTGTT GGGTAAACCA CTATTGTTTA CTGTTGTTGA TACTACACGC AGTACAAAAT TGTGATTATG TGTGATTATG TGTGATTATG TGTGATTATG
6000 TAAAAACT AACCTTAAAG AGTACCTACG ACATGGGGAG GAATATGAT TACAGTTTAT TTTTCAACT TTTTCAACT TTTTCAACT TTTTCAACT
6100 ACATACATAC ATCTATGAAA TTTCCACTAT TTTGAGGACT GGAATTTTGG TCTACAACCT CCCCAGGAG GCACACTAGA AGATCTTAT AGATTTTATG
6200 CCGAGCCAA TTTGTGCGA AAACATACAC CTCCAGCACC TAAAGAAGAT GATCCCTTAA AAAAAACAC TTTTGGGAA TTTTGGGAA TTTTGGGAA
6300 TCTGCGACG CTAGTCAAGT TTTCTTAGG ACGCAAAAT TTTACTAGA CAGGATGAA GGCCAAACCA AAATTTTACAT TAGGAAAAGT AAAAGGATCA
6400 CCGACCCCTT CATCTACCTC TACAACCTCT AAACGCAAAA AACGTAAGCT GAAAGTATTG TATGATGTT ATAAACACT GTGTATGTT TTTTAAATG
6500 GTATGTGCTT GTATGTGCTT GAAAATATTA AGTTGATGT GTGTTGATG TATGGTATA ATAAACACT GTGTATGTT TTTTAAATG TTTTAAATG
6600 ATTTGTGCTT GCAACATAAA TAAAATTTAT TTTTCAACT CTACTAATG TTTTGTGGT TTTTGTGGT TTTTGTGGT TTTTGTGGT TTTTGTGGT TTTTGTGGT
6700 TCTATGCTAG CAACATGTT TAAAAGTGGT TTTAAGTGGT TTTAAGTGGT TTTAAGTGGT TTTAAGTGGT TTTAAGTGGT TTTAAGTGGT TTTAAGTGGT
6800 GTTTTATACA CTGCACATG TGCACACTT GAATCTACT GTACATGTT TTTGCTGTC GTGCAAAAG TTTGCTGTC TTTGCTGTC TTTGCTGTC TTTGCTGTC
6900 CACATATTTT TGGCTGTTT TAATGATAT TTTGGCTAAG TTTGCTGTC GTGCAAAAG TTTGCTGTC TTTGCTGTC TTTGCTGTC TTTGCTGTC TTTGCTGTC
7000 GTGAAAAGGT TAGTCAACA TTTTCTATT TTTAAAAGTGC ACATGGGTT GTGCAAAAG TTTGCTGTC GTGCAAAAG TTTGCTGTC TTTGCTGTC TTTGCTGTC
7100 CTAA

HPV 16: GENE SEQUENCE OF HPV 16 (Seedorf et al 1985)




**PHOTOGRAPH 1: EPPENDORF TUBES IN RACK DURING
RNA EXTRACTION PROCESS**




PHOTOGRAPH 2:

EPPENDORF TUBES DURING RNA EXTRACTION

**PROCESS CONTAINING UPPER CLEAR AQUEOUS PHASE & LOWER RED
PHENOL PHASE**



**GEL IMAGE 1: BAND SIZES A) MOLECULAR WEIGHT MARKER
B) SAMPLE**



GEL IMAGE 2: RT-PCR PRODUCTS DEMONSTRATING

*E6/E6*I/E6*II* GENES WITH S3/S4 PRIMERS

SAMPLES & CELL LINES

Anticipated band sizes: *E6* – 525 bp *E6*I* – 343bp *E6*II* – 226bp




**GEL IMAGE 3: RT-PCR PRODUCTS OF SAMPLES & CELL-LINES
WITH S3/S4 PRIMERS**



GEL IMAGE 4: RT-PCR SHOWING SPECIMENS AND GAPDH AS CONTROL



GEL IMAGE 5: NESTED PCR PRODUCTS OF SAMPLES AND CELL-LINES USING S1/2 PRIMERS DEMONSTRATING *E6/E6*1/E6* GENES




GEL IMAGE 6: RT-PCR PRODUCTS OF CELL – LINES AND CONTROLS INCLUDING NEGATIVE CONTROL



GEL IMAGE 7:

ABOVE: NESTED PCR PRODUCTS OF SAMPLES AND CELL LINES USING S1/2 PRIMERS.

BELOW: RT-PCR PRODUCTS USING S3/4 PRIMERS.



**GEL IMAGE 8: NESTED RT-PCR PRODUCTS DEMONSTRATING
*E6/E6*I/E6*II* GENES WITH S1/S2 PRIMERS IN
SAMPLES & CELL- LINES (MWM= molecular
weight marker) (-) = negative cell line**

REFERENCES

Abma JC, Chandra A, Musher WD, et al. Fertility, family planning and women's health: new data from the 1995 national survey of family growth. *Vital Health Statistics* 1997; 19: 1 – 114.

Ahdieh L, Klein RS, Burk R, et al. Prevalence, incidence and type-specific persistence of human papillomavirus in human immunodeficiency virus (HIV)-positive and HIV-negative women. *J Infect Dis* 2001; 184: 682 – 690.

Anderson GL, Judd HL, Kaunitz AM, et al. Effects of estrogen plus progestin on gynecologic cancers and associated diagnostic procedures: the Women's Health Initiative randomized trial. *J Am Med Association* 2003; 290: 1739 – 1748.

Andolsek L, Kovacu J, Kozuh M, Litt B. Influence of oral contraceptives on the incidence of premalignant and malignant lesions of the cervix. *Contraception* 1983; 28: 505 – 519.

Anttila T, Saikku P, Koskela P, et al. Serotypes of *Chlamydia trachomatis* and risk for development and risk for development of cervical squamous cell carcinoma. *J Am Med Assoc* 2001; 285: 47 – 51.

Appleby P, Beral V, Berrington D, et al.. An International Collaboration of Epidemiological Studies of Cervical Cancer, Cervical Cancer and Hormonal Contraceptives: collaborative re-analysis of individual data for 16573 women with cervical cancer and 35509 women without cervical cancer from 24 epidemiological studies. *Lancet* 2007; 370: 1609 – 1621.

Arbeit JM, Howley PM, Hanahan D. Chronic estrogen induced cervical and vaginal squamous carcinogenesis in human papillomavirus type 16 transgenic mice. *Proc Natl Acad Sci USA* 1996; 93: 2930 – 2935

Arellano M, Moreno S. Regulation of CDK/cyclin complexes during the cell cycle. *Int J Biochem Cell Biol* 1997; 29: 559 – 573.

Arends MJ, Buckley CH, Wells M. Aetiology, pathogenesis and pathology of cervical neoplasia. *J Clin Pathol* 1998; 51: 96 – 103.

Atalah E, Urteaga C, Rebolledo A et al. Diet, smoking and reproductive history as risk factor for cervical cancer. *Rev Med Chil* 2001; 129: 597 – 603.

Ateka GK. HIV / AIDS. Global impact and human rights – A Southern African perspective. *AIDS Scan* 2000; 2: 3 - 4

Ault KA. Effect of prophylactic human papillomavirus L1 virus-like particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3 and adenocarcinoma in-situ: a combined analysis of four randomized clinical trials. *Lancet* 2007; 369: 1861 – 1868.

Badal V, Chuang LS, Tan EH, et al. CpG methylation of human papillomavirus type 16 DNA in cervical cancer cell lines and in clinical specimens: genomic hypomethylation correlates with carcinogenic progression. *J Virol* 2003; 77: 6227 – 6234

Bahnassy AA, Zekri AR, Saleh M, Lotayef M, Moneir M, Shawki O. The possible role of cell cycle regulators in multistep process of HPV-associated cervical carcinoma. *BMC Clin Pathol* 2007; 7: 4.

Barbosa MS, Schlegel R. The E6 and E7 genes of HPV-18 are sufficient for inducing two-stage in vitro transformation of human keratinocytes. *Oncogene* 1989; 4: 1529 – 1532.

Barkan SE, Melnick SL, Preston-Martin S, et al. The Women's Interagency HIV Study. WIHS Collaborative Study Group. *Epidemiology* 1998; 9: 117 – 125.

Barton SE, Maddox PH, Jenkins D, Edwards R, Cuzick J & Singer A. Effect of cigarette smoking on cervical epithelial immunity: A mechanism for neoplastic change? *Lancet* 1988; 2: 652 – 654.

Bedell MA, Hudson JB, Golub TR et al. Amplification of human papillomavirus genomes *in vitro* is dependent on epithelial differentiation. *J Virol* 1991; 65: 2254 – 2260.

Beijnen JH. P53 selected as molecule of the year 1993. *Pharmacy World Science* 1993; 16: 1.

Beral V, Hannaford P, Kay C. Oral contraceptive use and malignancies of the genital tract: results from The Royal College of General Practitioners Oral Contraceptive Study. *Lancet* 1988; 2: 1331 – 1335.

Bertram CC. Evidence for practice: oral contraception and risk of cervical cancer. *J Am Acad Nurse Pract* 2004; 16: 455 – 461.

Bhattacharya P, Sengupta S. Predisposition to HPV 16/18-related cervical cancer because of praline homozygosity at codon 72 of p53 among Indian women is influenced by HLA-B*07 and homozygosity of HLA-DQB1*03. *Tissue Antigen* 2007; 70: 283 – 293.

Blossom DB, Beigi RH, Farrell JJ, Mackay W, Qadadri B, Brown DR et al. Human papillomavirus genotypes associated with cervical cytologic abnormalities and HIV infection in Ugandan women. *J Med Virol.* 2007; 79: 758-765

Boccalon M, Tirelli U, Sopracordeme F, Vacchar E. Intraepithelial and invasive cervical neoplasia during HIV infection. *Eur J Cancer* 1996; 32A: 2212 – 2217.

Bosch FX, Lorincz A, Munoz N. The casual relationship between human papillomavirus and cervical cancer. *J Clin Pathol* 2002; 55: 244 – 265

Bosch FX, Burchell AN, Schiffman M, Giuliano AR, de Sanjose S, Bruni L, et al. Epidemiology and natural history of human papillomavirus infections and type-specific implication in cervical neoplasia. *Vaccine* 2008; 26S (Suppl) K1-K16

Bosch FX, Manos MM, Munoz N et al. The International Biological Study on Cervical Cancer (IBSCC) Study Group. Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. *J Natl Cancer Inst* 1995; 87: 796 – 802.

Bosch FX, Qiao Y-L, Castellsague X. The epidemiology of human papillomavirus infection and its association with cervical cancer. *Int J Gynecol Obstet* 2006; 94 Suppl: S8 – S21.

Boshart M, Gissmann L, Ikenberg H, Kleinheinz A, Scheurlen W, zur Hausen H. A new type of papillomavirus DNA, its presence in genital cancer biopsies and in cell lines derived from cervical cancer. *EMBO J* 1984; 3: 1151-1157.

Bosetti C, Negri E, Trichopoulos D, Franceschi S, Beral V, Tzonou A, Parazzini F, Greggi S, La Vecchia C. Long-term effects of oral contraceptives on ovarian cancer risk. *Int J Cancer*. 2002 Nov 20;102:262-5.

Bouallaga I, Teissier S, Yaniv M, Thierry F. HMG-1(Y) and the CBP/p300 coactivator are essential for human papillomavirus type 18 enhanceosome transcriptional activity. *Mol Cell Biol* 2003; 23: 2329 – 2340.

Boyd JT & Doll R. A study of the aetiology of carcinoma of the cervix uteri: *Br J Cancer* 1964; 18: 419 – 434

Boyer SN, Wazer DE, Band V. E7 protein of human papillomavirus 16 induces degradation of retinoblastoma protein through the ubiquitin-proteasome pathway. *Cancer Research* 1996; 56: 4620 – 4624

Breitburd F, Croissant O & Orth G. Expression of HPV type 1 E4 gene products in warts. In: *Cancer cells Papillomavirus*, 1987; pp 115 –122. Steinberg BM, Brandsma JC & Taichman LB, eds. Cold Spring Harbor, Cold Spring harbor, New York.

Brinton LA. Epidemiology of cervical cancer-overview. In Munoz N, Bosch FX, Shah KV and Meheus A, eds. The epidemiology of cervical cancer and human papillomavirus (IARC Scientific Publications NO 119). Lyon, International Agency for Research on Cancer. 1992: 3 -52

Brinton LA, Hamman RF, Huggins GR, Lehman HF, et al. Sexual and reproductive risk factors for invasive squamous cell cancer of the cervix. J Natl Cancer Inst 1987; 79: 23 - 30

Brinton LA, Reeves WC, Brenes MM et al. The male factor in the etiology of cervical cancer among sexually monogamous women. Int J Cancer 1989; 44: 199 - 203

Brinton LA, Reeves WC, Brenes MM, et al. Oral contraceptive use and risk of invasive cervical cancer. Int J Epidemiol 1990; 19: 4 – 11.

Brinton LA, Schairer C, Haenszel W, Stolley P, Lehman HF, Levine R & Savitz DA. Cigarette smoking and invasive cervical cancer. JAMA 1986; 255: 3265 – 3269.

Brock KE, Berry G, Brinton LA, Kerr C, MacLennan R, Mock PA, Shearman RP. Sexual, reproductive and contraceptive risk factors for carcinoma-in-situ of the uterine cervix in Sydney. Med J Aust. 1989 Feb 6;150:125-30.

Brookstein R, Lee LH. Molecular genetics of the retinoblastoma suppressor gene. *Crit Rev Oncog* 1991; 2: 211 – 227.

Buckley JD, Harris RWC, Doll R et al. Case-control study of the husbands of women with dysplasia or carcinoma of the cervix uteri. *Lancet* 1981; 2: 1010-1015

Burnett TS, Sleeman JP. Uneven distribution of methylation sites within the human papillomavirus 1a genome: possible relevance to viral gene expression. *Nucleic Acids Res* 1984; 12: 8847 – 8860.

Castle PE, Wacholder S, Lorincz AT, et al. A prospective study of high-grade cervical neoplasia risk among human papillomavirus-infected women. *J Natl Cancer Inst USA* 2002; 94: 1406 – 1414.

Castle PE, Walker JL, Schiffman M, Wheeler CM. Hormonal contraceptive use, pregnancy and parity, and the risk of cervical intraepithelial neoplasia 3 among oncogenic HPV DNA-positive women with equivocal or mildly abnormal cytology. *Int J Cancer* 2005; 117: 1007 – 1012.

Castellsague X, Diaz M, de Sanjose S, Munoz N, Herrero R, Franceschi S, et al. Worldwide human papillomavirus etiology of cervical adenocarcinoma and its co-factors: implications for screening and prevention. *J Natl Cancer Inst USA* 2006; 98: 303 – 315.

Castellsague X, Munoz N, Cofactors in human papillomavirus carcinogenesis-role of parity, oral contraceptives and tobacco smoking. *J Natl Cancer Inst USA* 2003; 31: 20 – 28.

CDC Expands definition for AIDS. *ASHA* 1993; 35: 11 – 12.

Chakrabarti O, Krishna S. Molecular interactions of high-risk human papillomaviruses E6 and E7 oncoproteins: implications for tumour progression. *J Biosci* 2003; 28: 337 – 348.

Chan W, Klock G & Bernard H-V. Progesterone and glucocorticoid- response elements occur in the long control regions of several human papillomaviruses involved in anogenital neoplasia. *J Virol* 1989; 63: 3261 – 3269.

Chan YM, Ng TY, Ngan HY, Wong LC. Screening for HIV infection in women with newly diagnosed cervical cancer. *Gynecol Oncol* 2004; 92: 300 – 303

Chang AR. Hormonal contraceptives, human papillomaviruses and cervical cancer: some observations from a colposcopy clinic. *Aust NZ J Obstet Gynaecol* 1989; 29: 329 – 331.

Chellapan S, Kraus V, Kroger B et al. Adenovirus E1A, Simian virus 40 tumour antigen, and Human Papillomavirus E7 protein share the capacity to disrupt the interaction

between transcription factor E2F and the retinoblastoma gene product. Proc Natl Acad Sci USA 1992; 89: 4549 – 4553.

Chen JJ, Reid CE, Band V, Androphy EJ. Interaction of papillomavirus E6 oncoproteins with a putative calcium binding protein. Science 1995; 269: 529 – 531.

Chin KM, Sidhu JS, Janssen RS et al. Invasive cervical cancer in human immunodeficiency virus-infected and uninfected hospital patients. Obstet Gynecol 1998; 92: 83-87

Chirenje ZM. HIV and cancer of the cervix. Best Practice & Res Clin Obstet Gynaecol 2005; 19: 269 – 276.

Chirenje ZM, Rusakaniko S, Akino V, et al. Effect of HIV disease in treatment outcome of cervical squamous intraepithelial lesions among Zimbabwean women. J Lower Gen Tract Dis 2003; 7: 16 – 21.

Chong T, Apt D, Gloss B, Isa M & Bernard H-V. The enhancer of human papillomavirus type 16; binding sites for the ubiquitous transcription factors oct-1, NFA, TEF – 2, NFI and AP – I participate in epithelial cell-specific transcription. J Virol 1991; 65: 5933 – 5943.

Choo KB, Pan CC, Han SH. Integration of human papillomavirus type 16 into cellular DNA of cervical carcinoma: preferential deletion of the E2 gene and invariable retention of the long control region and the E6/E7 open reading frames. *Virology* 1987; 161: 259 – 261.

Chung TK, Cheung TH, Wang VW, Yu MY, Wong YF. Microsatellite instability, expression of hMSH2 and hMLH1 and HPV infection in cervical cancer and their clinicopathological association. *Gynecol Obstet Invest* 2001; 52: 98 – 103.

Chung SH, Wiedmeyer K, Shai A, Korach KS, Lambert PF. Requirement for estrogen receptor α 1a mouse model for human papillomavirus-associated cervical cancer. *Cancer Res* 2008; 68: 9928-9934.

Chung SH, Lambert PF. Prevention and treatment of cervical cancer in mice using estrogen receptor antagonists. *Proc Natl Acad Sci USA*. 2009; 106: 19467 – 19472.

Cibula D, Gompel A, Mueck AO, La Vecchia C, hannafor PC, Skouby SO, Zikan M, Dusek L. Hormonal contraception and risk of cancer. *Hum Reprod Update* 2010; 16: 631 – 650.

Ciuffo G. Innesso positivo con filtrato di verucca volgare. *Giorn Ital Mal Venereal* 1907; 48: 12-17

Clarke BA, Chetty R, Moodley M. Microsatellite analysis of early stage uterine cervical squamous carcinoma. *Int J Surg Pathol* 2003; 11: 253 - 260

Clarke B, Chetty R. Postmodern cancer: the role of human immunodeficiency virus in uterine cervical cancer. *Mol Pathol* 2002; 55: 19 – 24.

Clarke EA, Hatcher J, McKeown-Eyssen GE, et al. Cervical dysplasia: association with sexual behaviour, smoking and oral contraceptive use. *Am J Obstet Gynecol* 1985; 151: 612 – 616.

Clarke EA, Morgan RW & Newman AM. Smoking as a risk factor in cancer of the cervix: Additional evidence from a case-control study *Am J Epidemiol* 1982; 115: 59 – 66.

Clere N, Bermont L, Fauconnet S, Lascombe I, Saunier M, Vettoretti L, et al. The human papillomavirus type 18 E6 oncoprotein induces vascular endothelial growth factor (VEGF 121) transcription from the promoter through a p53-independent mechanism. *Exp Cell Res* 2007; 313: 3239 – 3250.

Clifford GM, Gallus S, Herrero R, Munoz N, Snijders PJ, Vaccarella S, et al. Worldwide distribution of human papillomavirus type distribution. *Cancer Res* 2006; 66: 1218 – 1224.

Clifford GM, Concalves MA, Franceschi S. HPV and HIV Study group. Human papillomavirus types among women infected with HIV: a meta-analysis. *AIDS* 2006; 20: 2337 – 2344.

Clifford GM, Gallus S, Herrero R et al. Worldwide distribution of human papillomavirus types in cytologically normal women in the International Agency for Research on Cancer HPV prevalence surveys: a pooled analysis. *Lancet* 2005; 366: 991 – 998.

Clifford GM, Smith JS, Plummer M, Munoz N, Franceschi S. Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis. *Br J Cancer* 2003; 88: 63 – 73.

Cogliano V, Grosse Y, Baan R, Straif K, Secretan B, el Ghissassi F. Carcinogenicity of combined oestrogen-progesterone contraceptives and menopausal treatment. *Lancet Oncol* 2005; 6: 552 – 553.

Cohen ME, Graham ME, Lovrez N, Bache PJ, Robinson PJ, Reddel RR. Protein composition of catalytically active human telomerase from immortal cells. *Science* 2007; 315: 1850 – 1853.

Coker AL, Sanders LC, Bond SM, et al. Hormonal and barrier methods of contraception, oncogenic human papillomaviruses and cervical squamous intraepithelial development. *J Women's Health Gender Based Med* 2001; 10: 441 – 449.

Cole S, Danos O. Nucleotide sequence and comparative analysis of the human papillomavirus type 18 genome. Phylogeny of papillomaviruses and repeated structure of the E6 and E7 gene products. *J Mol Biol* 1987; 193: 599 – 609.

Coleman N, Birley HDL, Renton AM, Hanna NF, Ryait BK, Byrne M, et al. Immunological events in regressing genital warts. *Am J Clin Pathol* 1994; 102: 768 – 774.

Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53297 women with breast cancer and 100239 women without breast cancer from 54 epidemiological studies. *Lancet* 1996; 347: 1713 – 1727.

Cone RW, Minson AC, Smith MR, McDougall JK. Conservation of HPV 16 E6/E7ORF sequences in a cervical carcinoma. *J Med Virol* 1992; 37: 99 – 107.

Cook T, Storey A, Almond N, Osborne K, Crawford L. Human Papillomavirus type 16 cooperates with activated *ras* and *fos* oncogenes in the hormone-dependent transformation of primary mouse cells. *Proc Natl Acad Sci USA* 1988; 85:8820 – 8824.

Cornelissen MT, Smits HL Breit MA, van den Tweel JG, Struyk AP, van der Noordaa J, ter Schegget J. Uniformity of the splicing pattern of the E6/E7 transcripts in human papillomavirus type 16-transformed human fibroblasts, human cervical premalignant lesions and carcinomas. *J Gen Virol* 1990; 71: 1243 – 1246.

Cripe TP, Alderborn A, Anderson RD, Parkkinen S, Bergman B, Hangen TH, Petterson V and Turek LP. Transcriptional regulation of the human papillomavirus 16 E6-E7 promoter by keratinocyte-dependent enhancer and by viral E2 transactivator and repressor gene products: Implication for cervical carcinogenesis. *EMBO J* 1987; 6: 3745 – 3753.

Crook T, Wrede D, Vousden KH. P53 point mutation in HPV negative human cervical carcinoma cell lines. *Oncogene* 1991; 6 : 873 – 875.

Cronje HS. Screening for cervical cancer in developing countries. *Int J Gynecol Obstet* 2004; 84: 101 – 108.

Cullen AP, Reid R, Campion M, Lorincz AT. Analysis of the physical state of different human papillomavirus DNA in intraepithelial and invasive cervical neoplasia. *J Virol* 1991; 65: 606 – 612.

Cuzick J, de Stavola B, McCance D, Ho TH et al. A case-controlled study of cervix cancer in Singapore. *Brit J Cancer* 1989; 60:238 - 243.

Daniel B, Mukherjee G, Seshadri L et al. Changes in the physical state and expression of human papillomavirus type 16 in the progression of cervical intraepithelial neoplasia lesions analysed by PCR. *J Gen Virology* 1995; 76: 2589 – 2593.

Deacon JM, Evans CD, Yule R, et al. Sexual behaviour and smoking as determinants of cervical HPV infection and of CIN 3 among those infected: a case-control study nested within the Manchester cohort. *Br J Cancer* 2000; 83: 1565 – 1572.

De Cremoux P, de la Rochefordiere A, Savignoni A, Kirova Y, Alran S, Fourchette V, et al. Different outcomes of invasive cervical cancer associated with high-risk versus intermediate-risk HPV genotype. *Int J Cancer* 2009; 124: 778-782

De Lange T. Shelterin: the protein complex that shapes and safeguards human telomeres. *Genes Dev* 2005; 19: 2100 – 2110.

Delgado-Rodriguez M, Sillero-Arenas M, Martin-Moreno JM, Galvez-Vargas R. Oral contraceptives and cancer of the cervix uteri: A meta-analysis. *Acta Obstet Gynecol Scand* 1992; 71: 368 – 376.

Delvenne P, Herman L, Kholod N, Caberg JH, Herfs M, Boniver J, et al. Role of hormone cofactors in the human papillomavirus-induced carcinogenesis of the uterine cervix. *Mol Cell Endocrinol* 2007; 264: 1 – 5.

Demers GW, Espling E, Harry JB, Etscheid BG, Galloway DA. Abrogation of growth arrest by human papillomavirus type 16 E7 is mediated by sequences required for transformation. *J Virol* 1996; 70: 6862 – 6869.

Denny L, Boa R, Williamson AL, Allan B, Hardie D, Stan R, Meyer L. Human papillomavirus infection and cervical disease in human immunodeficiency virus-1-infected women. *Obstet Gynecol* 2008; 111: 1380 – 1387.

Denny L, Kuhn L, Pollack AE, Wright TC. Prevalence of visible disruption of cervical epithelium and cervical ectopy in African women using Depo-Provera. *Contraception* 1999; 59: 363 – 367.

De Villiers EM, Fauquet C, Broker TR, Bernard HU, zur Hausen H. Classification of papillomaviruses. *Virology* 2004; 324: 17 – 27.

De Villiers EM, Gissmann L & zur Hausen H. Molecular cloning of viral DNA from human genital warts. *J Virol* 1981; 40: 932 – 935

De Villiers EM. Relationship between steroid hormone contraceptives and HPV, cervical intraepithelial neoplasia and cervical carcinoma. *Int J Cancer* 2003; 103: 705 – 708.

De Vet HC, Knipschild PG, Sturmans F. The role of sexual factors in the etiology of cervical dysplasia. *Int J Epidemiol* 1993; 22: 798 – 803.

De Vuyst H, Steyaert S, Van Renterghem L, Claeys P, Muchiri L, Sitati S et al. Distribution of human papillomavirus in a family planning population in Nairobi, Kenya. *Sex Transm Dis.* 2003; 30: 137-42

Diczfalusy E. Oral contraception: where do we stand? *Contemp Rev Obstet Gynaecol* 1992; 4: 148 – 153.

Doorbar J. Late stages of papillomavirus life cycle. *Papillomavirus Rep* 1998; 9: 119 – 126.

Dostatni N, Thierry F, Yaniv M. A dimer of BPV-1 E2 containing protease resistant core interacts with its DNA target. *EMBO J* 1988; 7: 3807 – 3816.

Duensing S, Lee LY, Duensing A et al. The human papillomavirus type 16 E6 and E7 oncoproteins co-operate to induce mitotic defects and genomic instability by uncoupling centrosome duplication from the cell division cycle. *Proc Natl Acad Sci USA*. 2000; 97: 10002 – 10007.

Duerr A, Kieke B, Warren D, et al. Human papillomavirus-associated cervical cytologic abnormalities among women with or at risk of infection with human immunodeficiency virus. *Am J Obstet Gynecol* 2001; 184: 584 – 590.

Dumeaux V, Alsaker E, Lund E. Breast cancer and specific types of oral contraceptives: a large Norwegian cohort study. *Int J Cancer* 2003; 105: 844 – 850.

Durst M, Gissman L, Ikenberg H, zur Hausen H. A papillomavirus DNA from a cervical carcinoma and its prevalence in cancer biopsy samples from different geographic regions.

Proc Natl Acad Sci U S A. 1983; 80: 3812-3815.

Dyson N. The regulation of E2F by pRB-family proteins. Genes Dev 1998; 12: 2245 – 2262.

Ebeling K, Nischan P, Schinder CH. Use of oral contraceptives and risk of invasive cervical cancer in previously screened women. Int J Cancer 1987; 39: 427 – 430.

Elbel M, Carl S, Spaderna S et al. A comparative analysis of the interactions of the E6 proteins from cutaneous and genital papillomaviruses with p53 and E6AP in correlation of their transforming potential. Virology 1997; 239: 132 – 149

Ellerbrock TV, Chiasson MA, Bush TJ, Sun X-W et al. Incidence of cervical squamous intraepithelial lesions in HIV-infected women. JAMA 2000;283:1031 – 1037.

Elson DA, Riley RR, Lacey A, et al. Sensitivity of the cervical transformation zone to estrogen-induced squamous carcinogenesis. Cancer Res 2000; 60: 1267 – 1275.

Faculty of Family Planning and Reproductive Health Care Clinical Effectiveness Unit.

Faculty statement from the CEU on a new publication: WHO Selected Practice

Recommendations for Contraceptive Use Update. Missed pills: New recommendations. J

Fam Plann Reprod Health Care; 2005; 31: 153 - 155 

Fehrmann F, Laimins LA. Human papillomaviruses: Targeting differentiating epithelial cells for malignant transformation. *Oncogene* 2003; 22: 5201 – 5207.

Feng W, Xiao J, Zhang Z, Rosen DG, Brown RE, Liu J, Duan X. Senescence and apoptosis in carcinogenesis of cervical squamous carcinoma. *Mod Pathol* 2007; 20: 961 – 966.

Ferenczy A, Coutle F, Franco E, Hankins C. Human papillomavirus and HIV co-infection and the risk of neoplasias of the lower genital tract: a review of recent developments. *CMAJ* 2003; 169: 431 – 434

Ferlay J, Bray F, Pisani P, Parkin DM. GLOBOCAN 2002 cancer incidence. Mortality and prevalence worldwide. IARC CancerBase No 5 version 2.0 Lyon: IARC Press; 2004.

Fernandes TA, Lima GL, de Souza FC, Fernandes JV, Meissner RV. Evaluation of the polymorphisms in the exons 2 to 4 of the TP53 in cervical carcinoma patients from a Brazilian population. *Cell Mol Biol* 2008; 54 (Suppl): OL1025 – OL1031.

Fernandez E, Herrero R, La Vecchia C. Cervical cancer screening in Europe: what next? *Eur J Cancer* 2000; 36: 2272 – 2275.

Fordyce EJ, Wang Z, Kahn AR et al. Risk of cancer among women with AIDS in New York City. *AIDS Pub Policy J* 2000; 15: 95 – 104.

Franceschi S, Dal maso L, Arniani S, et al. Risk of cancer other than Kaposi's sarcoma and non-Hodgkin's lymphoma in persons with AIDS in Italy. Cancer and AIDS Registry Linkage Study. Br J Cancer 1998; 78: 966 – 970.

Franceschi S Dal Maso L, Pezzotti P et al. Incidence of AIDS-defining cancers after AIDS diagnosis among people with AIDS in Italy, 1986-1998. J Acquir Immune Defic Syndr 2003; 34: 84-90

Frattini MG, Hurst SD, Lim HB, Swaminathan S, Laimins LA. Abrogation of a mitotic checkpoint by E2 proteins from oncogenic human papillomaviruses correlate with increased tumour of the p53 tumour suppressor protein. EMBO J 1997; 16: 318 - 331

Fowler JR, Sayegh R. Cervical cancer prevention: more than just a Pap in a diverse Urban community. Current Women's Health Reveiws 2005, 1: 79 – 83

Franco EL, Filho NC, Villa LL et al. Correlation patterns of cancer relative frequencies with some socioeconomic and demographic indicators in Brazil. An ecologic study. Int J Cancer 1988; 41; 24-29

Franco EL, Villa LL, Ruiz A, Costa MC. Transmission of cervical human papillomavirus infection by sexual activity: differences between low and high oncogenic risk types. J Infect Dis 1995; 172: 756 – 763

Fujita M, Inoue M, Tanizawa O et al. Alterations of the p53 gene in human papillomavirus infection in cervical carcinoma. *Cancer* 1993; 72: 1272 – 1280.

Garcia-Closas R, Castellsague X, Bosch FX, et al. The role of diet and nutrition in cervical carcinogenesis: a review of recent evidence. *Int J Cancer* 2005; 117: 629 – 637.

Garnett GP. Role of herd immunity in determining the effect of vaccines against sexually transmitted disease. *J Inf Dis* 2005; 191 (Suppl 1): S97 – S106.

Gavric-Lovrec V, Takac I. use of various contraceptives and human papillomavirus 16 and 18 infections in women with cervical intraepithelial neoplasia. *Int J STD AIDS* 2010; 21: 424 – 427.

Gewin LC, Myers H, Kiyono T, Galloway DA. Identification of a novel telomerase repressor that interacts with the human papillomavirus type-16 E6/E6-AP complex. *Genes Dev* 2004; 18: 2269 – 2282.

Gichangi P, de Vuyst H, Estambale B, et al. HIV and cervical cancer in Kenya. *Int J Gynaecol Obstet* 2002; 76: 55 – 63.

Giles RH, Peters DJ, Breuning MH. Conjunction dysfunction: CBP/p300 in human disease. *Trends in Genetics* 1998; 14: 178 – 183.

Giuliano AR, Sedjo RL, Roe DJ, Harri R, Baldwi S, Papenfuss MR, et al. Clearance of oncogenic human papillomavirus infection: effect of smoking (United States). *Cancer Causes Control* 2002; 13: 839 – 846.

Guiliano AR, Harris AR, Sedjo RL, Baldwin S, Roe D, Papenfuss MR, et al. Incidence prevalence and clearance of type-specific human papillomavirus infections: the Young Women's Health Study. *J Infect Dis* 2002; 186: 462 - 469

Giuliano AR, Tortolero-Luna G, Ferrer E, et al. Epidemiology of human papillomavirus infection in men, cancers other than cervical and benign conditions. *Vaccine* 2008; 26(Suppl 10): K17 – K28.

Goedert JJ. The epidemiology of acquired immunodeficiency syndrome malignancies. *Semin Oncol* 2000; 27:390 – 401.

Goodman MT, McDuffie K, Hernandez B, et al. Association of methylenetetrahydrofolate reductase polymorphism C677T and dietary folate with the risk of cervical dysplasia. *Cancer Epidemiol Biomark Prev* 2001; 10: 1275 – 1280.

Graham S and Schotz W. Epidemiology of cancer of the cervix in Buffalo New York. *J Natl Cancer Inst* 1979; 63:23 – 27.

Gram IT, Macaluso M, Stalsberg H. Oral contraceptive use and the incidence of cervical intraepithelial neoplasia. *Am J Obstet Gynecol* 1992; 167: 40 – 44.

Grana X, Reddy P. Cell cycle-control in mammalian cells: Role of cyclins, cyclin-dependent kinases (CDKs), growth suppressor genes and cyclin-dependent kinase inhibitors (CKIs). *Oncogene* 1995; 11: 211 – 219.

Green J, Berrington de Gonzalez A, Smith JS, Franceschi S, Appleby P, Plummer M, Beral V. Human papillomavirus infection and use of oral contraceptives. *Br J Cancer* 2003; 88: 1713 – 1720.

Green S, Chambon P. Oestrogen induction of a glucocorticoid response gene by a chimaeric receptor. *Nature* 1987; 325: 25 – 78.

Grassmann K, Rapp B, Maschek H, Petry KU, Iftner T. Identification of a differentiation-inducible promoter in the E7 open reading frame of human papillomavirus type 16 (HPV 16) in raft cultures of a new cell line containing high copy numbers of episomal HPV-16 DNA. *J Virol* 1996; 70: 2339 – 2349.

Gupta S, Sodhani P, Sharma A, Sharma JK, Halder K, Charchra KL, et al. Prevalence of high-risk human papillomavirus type 16/18 infection among women with normal cytology: risk factor analysis and implications for screening and prophylaxis. *Cytopathol* 2009; 20: 249 – 255.

Hainaut P, Hernandez T, Robinson A. IARC Database of p53 gene mutations in human tumours and cell lines: updated compilation, revised formats and new visualization tools. *Nucleic Acids Res* 1998; 26: 205 – 213.

Hannaford PC, Selvaraj S, Elliot AM, Angus V, Iversen L, Lee AJ. Cancer risk among users of oral contraceptives: cohort data from the Royal College of General Practitioner's oral contraception study. *BMJ* 2007; 335: 651.

Harper DM, Franco EL, Wheeler C, Ferris DG, Jenkins D, Schuind A, et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomized controlled trial. *Lancet* 2004; 364: 1757 – 1765.

Harper DM, Franco EL, Wheeler CM, Moscicki AB, Romanowski B, Roteli-Martins CM, et al. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. *Lancet* 2006; 367: 1247 – 1255.

Harris TG, Miller L, Kulasingam SL, Feng Q, Kiviat NB, Schwartz SM, Koutsky LA. Depo-medroxyprogesterone acetate and combined oral contraceptive use and cervical neoplasia among women with oncogenic human papillomavirus infection. *Am J Obstet gynecol* 2009; 200: e1 – 8.

Hasan UA, Bates E, Takeshita F, Biliato A, Accardi R, Bouvard V, et al. TLR9 expression and function is abolished by the cervical cancer-associated human papillomavirus type 16. *J Immunol* 2007; 178: 3186 – 3197

Heard I, Tassie JM, Schmitz V et al. Increased risk of cervical disease among human immunodeficiency virus-infected women with severe immunosuppression and high human papillomavirus load. *Obstet Gynecol* 2000; 96: 403 – 409.

Helland A, Borresen-Dale AL, Peltomaki P, et al. Microsatellite instability in cervical and endometrial carcinomas. *Int J Cancer* 1997; 70: 499 – 501.

Hendrich B, Bird A. Mammalian methyltransferases and methyl-CpG-binding domains: proteins involved in DNA methylation. 2000. p55-74. In: PA Jones and PK Vogt (eds), *DNA methylation and Cancer*, Springer, Berlin, Germany.

Herrero R, Hildesheim A, Bratti C, et al. Population-based study of human papillomavirus infection and cervical neoplasia in rural Costa Rica. *J Natl Cancer Inst* 2000; 92: 464 – 474.

Herrero R, Brinton LA, Reeves WC et al. Sexual behaviour, venereal diseases, hygiene practices and invasive cervical cancer in a high-risk population. *Cancer* 1990a; 65: 380 – 386.

Herrero R, Brinton LA, Reeves WC et al. Injectable contraceptives and risk of invasive cervical cancer: evidence of an association. *Int J Cancer* 1990b; 46: 5 – 7.

Herrington CS. Human papillomaviruses and cervical neoplasia I: Classification, virology, pathology and epidemiology. *J Clin Pathol* 1994; 47: 1066 – 1072.

Hgan HYS, Tsao SW, Lin SS et al. Abnormal expression and mutations of p53 in cervical cancer- a study at protein, RNA and DNA levels, *Genitourin Med* 1997; 73: 54 – 58.

Hickman E, Picksley S, Vousden K. Cells expressing HPV 16 E7 continue cell cycle progression following DNA damage induced p53 activation. *Oncogene* 1994; 9: 2177 – 2181

Hilders CGJM, Ras L, van Eendenberg JDH, et al. Isolation and characterization of tumour-infiltrating lymphocytes from cervical carcinoma. *Int J Cancer* 1994; 57: 805 - 813

Hildesheim A, Herrero R, Castle PE, Wacholder S, Bratti MC, Sherman ME, et al. HPV cofactors related to the development of cervical cancer: results from a population-based study in Cosat Rica. *Br J Cancer* 2001; 84: 1219 – 1226.

Hildesheim A, Reeves WC, Brinton LA et al. Association of oral contraceptive use and human papillomaviruses in invasive cervical cancers. *Int J Cancer* 1990; 45: 860 – 864.

Hildesheim A, Wang SS. Host and viral genetics and risk of cervical cancer: a review. *Virus Res* 2002; 89: 229 – 240.

Hirai H, Roussel MF, Kato J-Y, Ashmun RA, Sherr CJ. Novel INK4 proteins, p19 and p18, are specific inhibitors of the cyclin D-dependent kinases CDK4 and CDK6. *Mol Cell Biol* 1995; 15: 2672 – 2681.

Hiscott J. Triggering the innate antiviral response through IRF-3 activation. *J Biol Chem* 2007; 282: 15325 – 15329.

Hoyo C, Cousins DS, Bisgrove EZ, Gaines MM, Schwingl PJ, Fortney JA. Depo medroxyprogesterone acetate (DMPA) and combined oral contraceptives and cervical carcinoma in-situ in women aged 50 years and under. *West Indian Med J.* 2004; 53: 406-412

Hubbert NL, Sedman SA, Schiller JT. Human papillomavirus type 16 E6 increases the degradation rate of p53 in human keratinocytes. *J Virol* 1992; 66: 6237 – 6241.

Huibregste JM, Scheffner M, Howley PM. Cloning and expression of the cDNA for E6-AP, a protein that mediates the interaction of the human papillomavirus E6 oncoprotein with p53. *Mol Cell Biol* 1993; 13: 775 – 784.

Hu L, Plafker K, Vorozhko V, Zuna RE, Hanigan MH, Gorbsky GJ, et al. Human papillomavirus 16 E5 induces bi-nucleated cell formation by cell-cell fusion. *Virology* 2009; 384: 125-134.

IARC. Human Papillomavirus. IARC Monographs on the evaluation of carcinogenic risk to humans. Vol 90 Lyon: IARC Press 2007

IARC. International Agency for Research on Cancer. Monographs on the evaluation of the carcinogenic risk to humans. Vol 72. Hormonal contraception and post-menopausal hormonal therapy, Lyon, France: IARC, 1999.

IARC monographs on the evaluation of carcinogenic risks to Humans Volume 91: Combined estrogen-progestogen contraceptives and combined estrogen-progestogen menopausal therapy, IARC Press, Lyon, France, 2008.

IARC. IARC monographs programme finds combined estrogen-progesterone contraceptives and menopausal therapy are carcinogenic to humans. Vol 167. Lyon, France 2005.

Illades-Aguilar B, Cortes-Malagon EM, Antonio-Vejar V, Zamudio-Lopez N, Alarcon-Romero LD, Fernandez-Tilapa G, et al. Cervical carcinoma in Southern Mexico: Human papillomavirus and co-factors. *Cancer Detect Prev* 2008; 32; 300-307

International PV Conference, 2000, pp368, Castellsagne X, Bosch FX, de Sanjose S et al, eds. Thau, SL. Barcelona.

Jacobson DL, Peralta L, Farmer M, et al. Relationship of hormonal contraception and cervical ectopy as measured by computerized planimetry to chlamydial infection in adolescents. *Sex Trans Dis* 2000; 27: 313 – 319

Jamieson DJ, Duerr A, Burk R, et al. Characterization of genital human papillomavirus infection in women who have or who are at risk of having HIV infection. *Am J Obstet Gynecol* 2002; 186: 21 – 27.

Joura EA, Leodolter S, Hernandez-Avila M, Wheeler CM, Perez G, Koutsky LA, et al. Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16 and 18) L1 virus-like particle vaccine against high-grade vulval and vaginal lesions: a combined analysis of three randomised clinical trials. *Lancet* 2007; 369: 1693 – 1702.

Kanai M, Shiozawa T, Xin L et al. Immunohistochemical detection of sex steroid receptors, cyclins and cyclin-dependent kinases in the normal and neoplastic squamous epithelia of the uterine cervix. *Cancer* 1998; 82: 1709 – 1719.

Kanda T, Kukimoto I. Human papillomavirus and cervical cancer. *Uirusu* 2006; 56: 219 – 230.

Kanodia LM, Fahey LM, Kast WM. Mechanisms used by human papillomaviruses to escape the host immune response. *Curr Cancer Drug Targets* 2007; 7: 79 – 89.

Kamradt MC, Mohideen N, Krueger E et al. Inhibition of radiation-induced apoptosis by dexamethasone in cervical carcinoma cell lines depends upon increased HPV E6E7. *Br J cancer* 2000; 82:1709 - 1716

Katzenellenbogen RA, Egelkrout EM, Vliet-Gregg P, Gewin LC, Gafkin PR, Galloway DA. NFX1-123 and poly(A)-binding proteins synergistically augment activation of telomerase in human papillomavirus type 16 E6-expressing cells. *J Virol* 2007; 81: 3786 – 3796.

Kessler II. Venereal factors in human cervical cancer: Evidence from marital clusters. *Cancer* 1977; 39: 1912 – 1919.

Kim HJ, Guo W, Park NH. HPV-16 E6 oncoprotein induces mutations via p53-dependent and independent pathways. *Oncol rep* 2000; 7: 707 - 712.

Kisseljov F, Sakharova O, Kondratjeva T . Cellular and molecular biological aspects of cervical intraepithelial neoplasia. *Int Rev Cell Mol Biol* 2008; 271: 35 – 95.

Kisseljov F, Semionova L, Samoylova E, et al. Instability of chromosome 6 microsatellite repeats in human cervical tumours carrying papillomavirus sequences. *Int J Cancer* 1996; 69: 484 – 487.

Kjaer SK, de Villiers E-M, Dahl C et al. Case-controlled study of risk factors for cervical neoplasia in Denmark I. Role of the “male factor” in women with one life time sexual partner. *Int J Cancer* 1991; 48: 39.

Kjellberg L, Hallmans G, Ahren AM, et al. Smoking, diet, pregnancy and oral contraceptive use as risk factors for cervical intraepithelial neoplasia in relation to human papillomavirus infection. *Br J Cancer* 2000; 82: 1332 – 1328.

Kobayashi A, Greenblatt RM, Anastos K, Minkoff H, Massad LS, Young M, et al. Functional attributes of mucosal immunity in cervical intraepithelial neoplasia and effects of HIV infection. *Cancer Res* 2004; 64: 6766 – 6774.

Koskela P, Anttila T, Bjorge T, et al. *Chlamydia trachomatis* infection as a risk factor for invasive cervical cancer. *Int J Cancer* 2000; 85: 35 – 39.

Koutsky LA, Ault KA, Wheeler CM, Brown DR, Barr E, Alvarez FB, et al. Proof of principle study investigators. A controlled trial of a human papillomavirus type 16 vaccine. *N Eng J Med* 2002; 347: 1645 – 1651

Koutsky LA, Galloway DA and Holmes KK. Epidemiology of genital human papillomavirus infection. *Epidemiol. Rev* 1988; 10: 122-163

Kristiansen E, Jenkins A, Holm R. Coexistence of episomal and integrated HPV 16 DNA in squamous cell carcinoma of the cervix. *J Clin Pathol* 1994; 47: 253 – 256.

Kumar V, Green S, Stack G, Berry M, Jin JR, Chambon P. Functional domains of the human estrogen receptor. *Cell* 1987; 51: 941 – 951.

Kumar KS, Tang SC, Pater MM, Pater A. Up-regulation of hormone response of human papillomavirus type 16 expression and increased DNA-protein binding by consensus mutations of viral glucocorticoid response elements. *J Med Virol* 1996; 50: 254 – 262.

Kutler DI, Wreesmann VB, Goberdhan A, et al. Human papillomavirus DNA and p53 polymorphisms in squamous cell carcinomas from Fanconi anaemia patients. *J Natl Cancer Inst USA*. 2003; 95: 1718 – 1721.

Lacey JV Jr, Brinton LA, Abbas FM, Barnes WA, Gravitt PE, Greenberg MD, et al. Oral contraceptives as risk factors for cervical adenocarcinomas and squamous cell carcinomas. *Cancer Epidemiol Biomarkers Prev* 1999; 8: 1079 – 1085.

La Ruche G, Ramon R, mensab-Ado I et al. Squamous intraepithelial lesions of the cervix invasive cervical cancer and immunosuppression induced by immunodeficiency virus in Africa. *Cancer* 1998; 82: 2401 – 2408

La Vecchia C, Altieri A, Franceschi S, Tavani A. Oral contraceptives and cancer. *Drug Saf* 2001; 24: 741 – 754.

La Vecchia C, Bosetti C. Benefits and risks of oral contraception on cancer. *Eur J Cancer Prev* 2004; 13: 467 – 470.

La Vecchia C. Depot medroxyprogesterone acetate, other injectable contraceptives and cervical neoplasia. *Contraception* 1994; 49: 223 – 230.

La Vecchia C, Franceschi S, Decarli A. Sexual factors, venereal diseases and the risk of intraepithelial and invasive cervical neoplasia. *Cancer* 1986; 58: 935 - 941

Le Bon A, Tough DF. Links between innate and adaptive immunity via type 1 interferon. *Curr Opin Immunol* 2002; 14: 432 – 436.

Lech MM, Ostrowska L. Risk of cancer development in relation to oral contraception. *Eur J Contracep Reprod Health Care* 2006; 11: 162 – 168.

Lehtinen M, Koskela P, Jellum E, et al. Herpes simplex virus and risk of cervical cancer: a longitudinal, nested case-control study in the Nordic countries. *Am J Epidemiol* 2002; 156: 687 – 692.

Lenehan JG, Leonard KC, Nandra S, Isaacs CR, Mathew A, Fisher WA. Women's knowledge, attitudes, and intentions concerning Human Papillomavirus vaccination:

findings of a waiting room survey of obstetrics-gynaecology outpatients. J Obstet Gynaecol Can. 2008; 30:489-99.

Levi JE, Kleter B, Quint WG, Fink MC, Canto CL, Matsubara R et al. High prevalence of human papillomavirus (HPV) infections and high frequency of multiple HPV genotypes in human immunodeficiency virus-infected women in Brazil. J Clin Microbiol. 2002; 40: 3341-5

Levi F, Pasche C, Lucchini F, La Vecchia C. Oral contraceptives and colorectal cancer. Dig Liver Dis 2003; 35: 85 – 87.

Levine AJ, Finlay CA, Hinds PW. p53 is a tumour suppressor gene. Cell 2004; (Suppl) S116: S67 – S69.

Loeb LA. Microsatellite instability: Marker of a mutator phenotype in cancer. Cancer Res 1994; 54: 5059 – 5063.

Lomalisa P, Smith T, Guidozi F. Human Immunodeficiency virus infection and invasive cervical cancer in South Africa. Gynecol Oncol 2000; 77: 1704 -1707

Longatto-Filho A, Hammes LS, Sarian LO, Roteli- Martins C, Derchain SF, Erzen M, et al. Hormonal contraceptives and the length of their use are not independent risk factors

for high-risk HPV infections or high-grade CIN. *Gynecol Obstet Invest* 2010 Dec 9 (Epub ahead of print, abstract).

Lowy DR, Solomon D, Hildesheim A, Schiller JT, Schiffman M. Human papillomavirus infection and the primary and secondary prevention of cervical cancer. *Cancer* 2008; 113: 1980 – 1993.

Madeleine MM, Daling JR, Schwartz SM et al. Human papillomavirus infection and long-term oral contraceptive use increase the risk of adenocarcinoma in-situ of the cervix. *Cancer Epidemiol Biomarkers Prev* 2001; 10: 171 – 177.

Maiman M, Fruchter RG, Guy L, et al. Human immunodeficiency virus infection and invasive cervical carcinoma. *Cancer* 1993; 71: 402 – 406.

Maltzman W, Czyzyk L. V irradiation stimulates levels of p53 cellular tumor antigen in nontransformed mouse cells. *Mol Cell Biol*; 1984; 4: 1689 – 1694.

Manos MM, Waldman J, Zhang TY, Greer CE, Eichinger G, Schiffman MH, Wheeler CM. Epidemiology and partial nucleotide sequence of four novel genital human papillomaviruses. *J Infect Dis.* 1994;170: 1096-9.

Mandelson MT, Daling JR, White E, Chu J, McKnight B. Further evidence that duration and recency of oral contraceptive use are associated with invasive cervical cancer

(Abstract) *Am J Epidemiol* 1990; 132: 77.

Mao C, Koutsky LA, Ault KA, Wheeler CM, Brown DR, Willey DJ, et al. Efficacy of human papillomavirus 16 vaccine to prevent cervical intraepithelial neoplasia: a

randomized controlled trial. *Obstet Gynaecol* 2006; 107: 18 – 27.

Martinez E, Givel F, Wahli W. The estrogen response element as an inducible enhancer.

DNA sequence requirements and conversion to a glucocorticoid response element.

EMBO J 1987; 6: 3719 – 3727

Mantovani F, Banks L. The human papillomavirus E6 protein and its contribution to malignant progression. *Oncogene* 2001; 20: 7874 – 7887.

Massad LS, Seaberg EC, Watts DH et al. Low incidence of invasive cervical cancer among HIV-infected US women in a prevention program. *AIDS* 2004; 18: 109 – 113.

Matsukura T, Koi S, Sugase M. Both episomal and integrated forms of human

papillomavirus type 16 are involved in invasive cervical cancers. *Virology* 1989; 172: 63 –

72.

Maucort-Boulch D, Plummer M, Castle PE, Demuth F, Safaelan M, Wheeler CM, Schiffman M. Predictors of human papillomavirus persistence among women with equivocal or mildly abnormal cytology. *Int J Cancer* 2010; 126: 684 – 691.

Mbulaiteye SM, Parkin DM, Rabkin CS. Epidemiology of AIDS-related malignancies: an international perspective. *Hematol Oncol Clin North Am.* 2003; 17: 673 - 696.

McBride AA, Byrne JC, Howley PM. E2 polypeptides encoded by bovine papillomavirus type 1 form dimers through the common carboxyl-terminal domain: transactivation is mediated by the conserved amino terminal domain. *Proc Natl Acad Sci USA* 1989; 86: 510 – 514.

McDougall JK, Beckmann AM and Galloway DA. The enigma of viral nucleic acids in genital neoplasia. In: Peto R and zur Hausen H, eds, *Viral Etiology of cervical cancer* (Banbury Report 21), Cold Spring Harbor, NY, Cold Spring Harbor Press, pp 199 – 210, 1986.

McFarlane-Anderson N, Bazuaye PE, Jackson MD, Smikle M, Fletcher HM. Cervical dysplasia and cancer and the use of hormonal contraceptives in Jamaican women. *BMC Women's Health* 2008; 8: 9.

McMillan VM, Dennis GJ, Glimcher LH, Finkelman FD, Mond JJ. Corticosteroid induction of Ig+Ia-B cells *in vitro* is mediated via interaction with glucocorticoid cytoplasmic receptor. *J Immunol* 1988; 140: 2549 – 2555.

Mehal WZ, Lo Y-MD, Herrington CS et al. Role of human papillomavirus in determining the HLA- associated risk of cervical carcinogenesis, *J Clin Pathol* 1994; 47: 1077 – 1081.

Meisels A, Begin R, Schneider V. Dysplasias of uterine cervix: epidemiological aspects: role of age at first coitus and use of oral contraceptives. *Cancer* 1977; 40: 3076 – 3081.

Meisels A, Fortin R, Roy M. Condylomatous lesions of the cervix II. Cytologic, colposcopic and histopathologic study. *Acta Cytol* 1977; 21: 379-390

Meisels A & Morin C. Human papillomavirus and cancer of the uterine cervix. *Gynecol Oncol* 1981; 12: 8111 – 8123.

Melikian AA, Sun P, Prokoczy B et al. Identification of benzo[a]pyrene metabolites in cervical mucus and DNA adducts in cervical tissues in humans by gas chromatography-mass spectrometry. *Cancer Lett* 1999; 146: 127 – 134.

Mellone M, Rinaldi C, Massimi I, Petroni M, Veschi V, Talora C, et al. Human papillomavirus-dependent HMGA1 expression is a relevant step in cervical carcinogenesis. *Neoplasia* 2008; 10: 773 – 778.

Micali G, Nasca MR, Innocenzi D, Schwartz RA. Penile cancer. *J Am Acad Dermatol* 2006; 54: 369 – 391.

Middleton K, Peh W, Southern S, Griffin H, Sotlar K, Nakahara T, et al. Organization of human papillomavirus productive cycle during neoplastic progression provides a basis for selection of diagnostic markers. *J Virol* 2003; 77: 10186 – 10201.

Miller BA, Davidson M, Myerson D, Icenogle J, Lanier AP, Tan J, Beckmann AM. Human papillomavirus type 16 DNA in esophageal carcinomas from Alaska Natives. *Int J Cancer*. 1997 Apr 10;71:218-22.

Misra JS, Tandon P, Srivastava A, Das K, Chandrawati, Saxena NC. Cervical cytological studies in women inserted with Norplant-I contraceptive. *Diagn Cytopathol* 2003; 29: 136 – 139.

Mittal R, Tsutsumi K, Pater A, Pater M. Human papillomavirus type 16 expression in cervical keratinocytes: Role of progesterone and glucocorticoid hormones. *Obstet Gynecol* 1993; 81: 5 – 12.

Mitrani-Rosenbaum S, Tsvielli R, Tur-Kaspa R. Oestrogen stimulates the differential transcription of human papillomavirus type 16 in SiHa cervical carcinoma cells. *J Gen Virol* 1989; 70: 2227 – 2232.

Monsonego J, Magdalena H, Catalan F, et al. Estrogen and progesterone receptors in cervical human papillomavirus related lesions. *Int J Cancer* 1991; 48: 533 – 539.

Moodley M, Chetty R, Herrington CS. The role of steroid contraceptive hormones in the pathogenesis of invasive cervical cancer: A review. *Int J Gynecol Cancer* 2003; 13: 103 – 110.

Moodley M, Moodley J, Kleinschmidt I. Invasive cervical cancer and human immunodeficiency virus (HIV) infection: a South African perspective. *Int J Gynecol Cancer* 2001; 11: 194 - 197

Moodley M. Reduction in prevalence of invasive cervical cancer in KwaZulu Natal, South Africa: impact of the human immunodeficiency virus epidemic. *Int J Gynecol Cancer* 2006;16: 1036 – 1040.

Moodley M, Sewart S, Herrington CS, Chetty R, Pegoraro R. The interaction between steroid hormones, human papillomavirus type 16, E6 oncogene expression and cervical cancer. *Int J Gynecol Cancer* 2003; 13: 1 – 9.

Moreno V, Bosch FX, Munoz N, et al. Effect of oral contraceptives on risk of cervical cancer in women with human papillomavirus infection: The IARC multicentric case-controlled study. *Lancet* 2002; 359: 1085 – 1092.

Moreno V, Bosch FX, Munoz N, Meijer CJLM, Shah KV, Walboomers JMM, et al. IARC. Effect of oral contraceptives on risk of cervical cancer in women with human

papillomavirus infections: the IARC multicentric case-control study. *Lancet* 2002; 359: 1085 – 1092.

Moreno V, Bosch FX, Munoz N et al. The risk of cervical cancer in relation to hormonal contraceptives in women that are HPV-DNA carriers, pooled analysis of the IARC multicentric case-control study. In: 18th International PV conference, 2000 pp 129, Castellsague X, Bosch FX, de Sanjose S et al, eds. Thau, SL, Barcelona

Morozov A, Shiyonov P, Barr E, Leiden JM, Raychaudhuri P. Accumulation of human papillomavirus E7 protein bypasses G1 arrest induced by serum deprivation and by cell cycle inhibitor p21. *J Virol* 1997; 71: 3451 – 3457.

Moscicki AB, Ma Y, Wibbelsman C, Darrgh TM, Powers A, Farhat S, Shiboski S. Rate of risks for regression of cervical intraepithelial neoplasia 2 in adolescents and young women. *Obstet gynecol* 2010; 116: 1373 – 1380.

Muller T, Hamm S, Bauer S. TLR9-mediated recognition of DNA. *Handb Exp Pharmacol* 2008; 183: 51 – 70.

Munger K and Phelps WC. The human papillomavirus E7 protein as a transforming and transactivating factor. *Biochemica et Biophysica Acta* 1993; 1155: 111 – 123.

Munger K, Werness BA, Dyson N, Phelps WC, Harlow E, Howley PM. Complex formation of human papillomavirus E7 proteins with the retinoblastoma tumour suppressor gene product. *EMBO J* 1989; 8: 4099 – 4105.

Muñoz N, Franceschi S, Bosetti C, Moreno V, Herrero R, Smith JS, Shah KV, Meijer CJ, Bosch FX. Role of parity and human papillomavirus in cervical cancer: the IARC multicentric case-control study. *Lancet* 2002; 359: 1093 – 1101.

Munoz N, Bosch FX, de Sanjose S, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. *New Eng J Med* 2003; 348: 518 – 527.

Munoz N, Bosch FX, Castellsague X, Diaz M, de Sanjose S, Hammouda D, et al. Against which human papillomavirus types shall we vaccinate and screen? The international perspective. *Int J Cancer* 2004; 111: 278 – 285.

Munoz N, Bosch FX, de Sanjose S, et al. The causal link between human papillomavirus and invasive cervical cancer: a population-based case-control study in Colombia and Spain. *Int J Cancer* 1992;52: 743 – 749.

Munoz N, Bosch X, Kaldor JM. Does human papillomavirus cause cancer? The state of the epidemiological evidence. *Br J Cancer* 1988; 57: 1 – 5.

Munoz N, Castellsague X, Berrington de Gonzalez A, Gissman L. HPV in etiology of human cancer. *Vaccine* 2006; (Suppl 3); 24: S3/1 – S3/10.

Nakagawa S, Yoshikawa H, Yasugi T et al. Ubiquitous presence of E6 and E7 transcripts in human papillomavirus – positive cervical carcinomas regardless of its type. *J Med Virol* 2000; 62: 251 – 256.

Narisawa-Saito M, Kiyono T. Basic mechanisms of high-risk human papillomavirus-induced carcinogenesis: roles of E6 and E7 proteins. *Cancer Sci* 2007; 98: 1505 – 1511.

Nees M, Geoghegan JM, Hyman T, Franks S, Miller L, Woodworth CD. Papillomavirus type 16 oncogenes downregulate expression of interferon-responsive genes and upregulate proliferation-associated and NF-kappaB-responsive genes in cervical keratinocytes. *J Virol* 2001; 75: 4283 – 4296.

Nielsen CM, Flores R, Harris RB, Abrahamsen M, papenfuss MR, Dunne EF, et al. Human papillomavirus prevalence and type distribution in male anogenital sites and semen. *Cancer Epidemiol Biomarkers Prev* 2007; 16: 1107 – 1114.

Newfield L, Bradlow HL, Sepkovic DW, Auburn K. Estrogen metabolism and the malignant potential of human papillomavirus immortalized keratinocytes. *Proc Soc Exp Biol Med* 1998; 217: 322 – 326.

Newton R, Ziegler J, Beral V, et al. A case-control study of human immunodeficiency virus infection and cancer in adults and children residing in Kampala, Uganda. *Int J Cancer* 2001; 92: 622 – 627.

New Zealand Contraception and Health Study Group. Risk of cervical dysplasia in users of oral contraceptives, intrauterine devices or depo- medroxyprogesterone acetate. *Contraception* 1994; 50: 431 – 441.

Nicol AF, Pires AR, de Souza SR, Nuovo GJ, Grinztejn B, Tristao A, et al. Cell-cycle and suppressor proteins expression in uterine cervix in HIV/HPV co-infection: comparative study by tissue micro-array (TMA). *BMC Cancer* 2008; 8: 289.

Nishimura M, Furumoto H, Kato T, Kamada M, Aono T. Microsatellite instability is a late event in the carcinogenesis of uterine cervical cancer 2000; 79: 201 – 206.

Norman SA, Berlin JA, Weber AL, et al. Combined effect of oral contraceptive use hormone replacement therapy on breast cancer risk in postmenopausal women. *Cancer Causes Control* 2003; 14: 933 – 943.

Obalek S, Jablonsa S, Beaudenon S, Walczak L, Orth G. Bowenoid papulosis of the male and female genitalia: risk of cervical neoplasia. *J Am Acad Dermatol* 1986; 14: 433-444

Oda H, Kumar S, Howley PM. Regulation of the src family tyrosine kinase Blk through E6-AP mediated ubiquitination. *Proc Natl Acad Sci USA*. 1999; 96: 9557 – 9562.

Ohwada M, Suzuki M, Kashiwagi H, Konishi F, Sato I. DNA replication error in endometrial carcinoma and complex atypical endometrial hyperplasia. *Cancer Genet Cytogenet* 1999; 114: 130 – 135.

Paglia P, Guzman CA. Keeping the immune system alerted against cancer. *Cancer Immunol Immunother* 1998; 46: 88-92

Palan PR, Mikhail ML, Basu J, Romney RL. Plasma levels of anti-oxidant beta-carotene and alpha tocopherol in uterine cervix dysplasias and cancer. *Nutr Cancer* 1991; 15: 13 – 20.

Parazzini F, La Vecchia C, Negri E, Cecchetti G and Fedele L. Reproductive factors and the risk of invasive and intraepithelial cervical neoplasia. *Br J Cancer* 1990; 59: 805 – 809.

Parkin DM, Wabinga H, Namboozee S et al. AIDS-related cancers in Africa: maturation of the epidemic in Uganda. *AIDS* 1999; 13: 2563 – 2570.

Pater A, Batyatpour M, Pater M. Oncogenic transformation by human papillomavirus type 16 deoxyribonucleic acid in the presence of progestins from oral contraceptives. *Am J Obstet Gynecol* 1990; 162: 1099 – 1103.

Pater MM, Mital R, Pater A. Role of steroid hormones in potentiating transformation of cervical cells by human papillomaviruses. *Trends Microbiology* 1994; 2: 229 – 234.

Patrick DR, Oliff A, Heimbrook DC. Identification of a novel retinoblastinoma gene product binding site on human papillomavirus type 16 E7 protein. *J Biol Chem* 1994; 269: 6842 – 6850.

Pavletich NP. Mechanisms of cyclin-dependent kinase regulation: Structure of CDK's, their cyclin activation and Cip and INK 4 inhibition. *J Mol Biol* 1999; 287: 821 – 828.

Peritz E, Ramcharan S, Frank J, Brown WL, Huang S, Ray R. The incidence of cervical cancer and duration of oral contraceptive use. *Am J Epidemiol* 1977; 106: 462 – 469.

Peters RK, Thomas D, Hagan DG, et al. Risk factors for invasive cervical cancer among Latinas and non-Latinas in Los Angeles County. *J Natl Cancer Inst USA* 1986; 77: 1063 – 1077.

Petry KU, Scheffel D, Bode U, et al. Cellular immunodeficiency enhances the progression of human papillomavirus-associated cervical lesions. *Int J Cancer* 1994; 57: 836 – 840.

Pett MR, Herdman MT, Palmer RD, Yeo GS, Shivji MK, Stanley MA, et al. Selection of cervical keratinocytes containing integrated HPV 16 associates with episome loss and an endogenous antiviral response. *Proc Natl Acad Sci USA*. 2006; 103: 3822 – 3827.

Pfister H. Relationship of papillomaviruses to anogenital cancer. *Obstet Gynecol Clin North Am* 1987; 14: 349-361

Phelps RM, Smith DK, Heilig CM, et al. Cancer incidence in women with or at risk for HIV. *Int J Cancer* 2001; 94: 753 – 757.

Pierantoni GM, Rinaldo C, Esposito F, Mottolese M, Soddu S, Fusco A. High mobility group A1 (HMGA1) proteins interact with p53 and inhibit its apoptotic activity. *Cell Death Differ* 2006; 13: 1554 – 1563.

Potischman N, Brinton LA. Nutrition and cervical neoplasia. *Cancer Causes Control* 1996; 7: 113 – 126.

Preston SN. The oral contraceptive controversy. *Am J Obstet Gynecol* 1971;111: 994 - 1007.

Prokopczk B, Cox JE, Hoffmann D, Waggoner SE. Identification of tobacco-specific carcinogen in the cervical mucus of smokers and non-smokers. *J Natl Cancer Inst USA* 1997; 89: 868 – 873.

Ramcharan S: The Walnut Creek Contraceptive Drug Study, A prospective study of the side-effects of oral contraceptives. Vol 1 DHEW Publication (NIH). Washington DC, United States Government Printing Office, 1974.

Ramoue F, Jacobs N, Miot V, et al. High intraepithelial expression of estrogen and progesterone receptors in the transformation zone of the uterine cervix. *Am J Obstet Gynaecol.* 2003; 189: 1660 – 1665.

Reeves R, Edberg DD, Li Y. Architectural transcription factor HMG1(Y) promotes tumor progression and mesenchymal transition of human epithelial cells. *Mol Cell Biol* 2001; 21: 575 – 594.

Reeves R. HMGA proteins: isolation, biochemical modifications and nucleosome interactions. *Methods Enzymol* 2004; 375: 297 – 322.

Reid R, Campion MJ. The biology and significance of human papillomavirus infections in the genital tract. *Yale J Biol Med* 1988; 61: 307 - 325

Reid R, Lorincz AT. Human papillomavirus and cervical cancer: Is the relationship causal or casual? Congress Proceedings: International Society of Colposcopy and Cervical Pathology, Rome. Italy 1990.

Rickert P, Seghezzi W, Shanahan F, Cho H, Lees E. Cyclin C and CDK 8 is a novel CTD kinase associated with RNA polymerase II. *Oncogene* 1996; 12: 2631 – 2640.

Rodriguez JA, Barros F, Carracedo A, Mugica-van Herckenrode CM. Low incidence of microsatellite instability in patients with cervical carcinomas. *Diagn Mol Pathol* 1998; 7: 276 – 282.

Romanczuk H, Thierry F, Howley PM. Mutational analysis of cis elements involved in E2 modulation of human papillomavirus type 16 p97 and type 18 p105 promoters. *J Virol* 1990; 64: 2849 – 2859.

Ronco LV, Karpova AY, Vidal M, Howley PM. Human papillomavirus 16 E6 oncoprotein binds to interferon regulatory factor-3 and inhibits its transcriptional activity. *Genes Dev* 1998; 12: 2061 – 2072.

Rosenstierne MW, Vinther J, Hansen CN, Prydsøe M, Norrild B. Identification and characterization of a cluster of transcription start sites located in the E6 ORF of human papillomavirus type 16. *J Gen Virol* 2003; 84: 2909 – 2920.

Rotkin ID. Adolescent coitus and cervical cancer: Associations of related events with increased risk. *Cancer Res* 1967; 27: 603 – 617.

Rous P and Beard JW. The progression to carcinoma of virus-induced rabbit papilloma (Shope) *J Experi Med* 1935; 62: 523 – 548.

Royansky N, Anteby SO. Gynecologic neoplasia in the patient with HIV infection. *Obstet Gynecol Surv* 1996; 51: 679 – 683.

Ruutu M, Wahiroos N, Syrjanen K, Johansson B, Syrjanen S. Effects of 17beta-estradiol and progesterone on transcription of human papillomavirus 16 E6/E7 oncogenes in caSki and SiHa cell lines. *Int J Gynecol cancer* 2006; 16: 1261 – 1218.

Sanchez-Perez A-M, Soriano S, Clarke AR, Gaston K. Disruption of the human papillomavirus type 16 E2 gene protects cervical carcinoma cells from E2F-induced apoptosis. *J Gen Virol* 1997; 78: 3009 – 3018.

Sasieni P. Cervical cancer prevention and hormonal contraception. *Lancet* 2007; 370: 1591 – 1592.

Scheffner M, Huibregste JM, Vierstra RD, Howley PM. The HPV-16 and E6-AP complex functions as a ubiquitin-protein ligase in the ubiquitination of p53. *Cell* 1993 ; 75: 495 – 505.

Scheffner M, Werness BA, Huibregste JM et al. The E⁶ oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. *Cell* 1990; 60: 1129 – 1136.

Schiffman M, Bauer HM, Hoover RN et al. Epidemiologic evidence showing that human papillomavirus infection causes most cervical intraepithelial neoplasia. *J Natl Cancer Inst* 1993; 85: 958 – 964.

Schiffman MH, Haley NJ, Felton JS, Andrews AW et al. Biochemical epidemiology of cervical neoplasia: Measuring cigarette smoke constituents in the cervix. *Cancer Res* 1987; 47: 3886 – 3888.

Schiffman M, Kjaer SK. Natural history of anogenital human papillomavirus infection and neoplasia. *J Natl Cancer Inst Monogr* 2003; 31: 14 – 19.

Schiller JT, Castellsague X, Villa LL, Hildesheim A. An update of prophylactic human papillomavirus L1 virus-like particle vaccine clinical trial results. *Vaccine* 2008; 26S: K53 – K61

Schlecht NF, Platt RW, Duarte-Franco E, et al. Human papillomavirus infection and time to progression and regression of cervical intraepithelial neoplasia. *J Natl Cancer Inst* 2003;95: 1336 – 1343.

Schneider HP, Mueck AO, Kuhl H. IARC monographs program on carcinogenicity of combined hormonal contraceptives and menopausal therapy. *Climacteric* 2005; 8: 311 - 316

Schneider V, Kay S and Lee HM. Immunosuppression as a high-risk factor in the development of condyloma acuminata and squamous neoplasia of the cervix. *Acta Cytol* 1983; 27: 220 – 224.

Schuman P, Ohmit SE, Klein RS et al. Longitudinal study of cervical squamous intraepithelial lesions in human immunodeficiency virus (HIV) seropositive and at-risk HIV-seronegative women. *J Infect Dis* 2003; 188: 128 – 136.

Schwartz TF. An ASO4-containing human papillomavirus (HPV) 16/18 vaccine for prevention of cervical cancer is immunogenic and well-tolerated in women 15-55 years old. American Society of Clinical Oncology, 2006, Annual Meeting, June 2-6, 2006.

Seedorf K, Kraemmer G, Duerst M, et al. Human papillomavirus type 16 DNA sequence. *Virology* 1985; 145: 181 – 185.

Shai A, Pitot HC, Lambert PF. p53 Loss synergizes with estrogen and papillomaviral oncogenes to induce cervical and breast cancers. *Cancer Res* 2008; 68: 2622 – 2631.

Shannon J, Thomas DB, Ray RM, Kestin M, Koetsawang S, Koetsawang A, Chitnarong K, Kiviat N, Kuypers J. Dietary risk factors for invasive and in-situ cervical carcinomas in Bangkok, Thailand. *Cancer Causes Control* 2002; 13: 691 -699.

Sherr CJ. The Pezcoller lecture: cancer cell cycles revisited. *Cancer Res.* 2000; 60: 3689 – 3695.

Sherris J, Herdman C, Elias C. Cervical cancer in the developing world. *West J Med* 2001; 175: 231- 233

Sherman ME, Kurman RJ. Evolving concepts in endometrial carcinogenesis: Importance of DNA repair and regulated growth. *Hum Pathol* 1998; 29: 1035 – 1038.

Shields TS, Brinton LA, Burk RD, Wang SS, Weinstein SJ, Ziegler RG et al. A case-control study of risk factors for invasive cervical cancer among U.S women exposed to oncogenic types of human papillomavirus. *Cancer Epidemiol Biomarkers Prev.* 2004; 13: 1574-82

Sima N, Wang W, Kong D, Deng D, Xu Q, Zhou J, et al. RNA interference against HPV 16 E7 oncogene leads to viral E6 and E7 suppression in cervical cancer cells and apoptosis via upregulation of Rb and p53. *Apoptosis* 2008; 13: 273 – 281.

Sitas F, Levin CV, Spencer D, et al. HIV and cancer in South Africa. *S Afr Med J* 1993; 83: 880 – 881.

Sitas F, Pacella-Norman R, Carrara H, et al. The spectrum of HIV-1 related cancers in South Africa. *Int J Cancer* 2000; 88: 489 – 492.

Slattery ML, Overall JC, Abbot TM, French TK, Robison LM, Gardner J. Sexual activity, contraception, genital infections and cervical cancer: Support for 2 sexual transmitted disease hypotheses. *Am J Epidemiol* 1989; 130: 248 – 258.

Smith C, Lilly S, Mann KP et al. AIDS-related malignancies. *Ann Med* 1998; 30: 323 – 344.

Smith JS, Green J, Berrington de Gonzalez A, et al. Cervical cancer and use of hormonal contraceptives: a systematic review. *Lancet* 2003; 361: 1159 – 1167.

Smith JS, Melendy A, Rana RK, Pimenta JM. Age-specific prevalence of infection with human papillomavirus in females: a global review. *J Adolesc Health*. 2008; 43: S5-25

Smith JS, Munoz N, Herrero R, et al. Evidence for *Chlamydia trachomatis* as a human papillomavirus cofactor in the etiology of invasive cervical cancer in Brazil and the Philippines. *J Infect Dis* 2002; 185: 324 – 331.

Smotkin D, Prokoph H, Wettstein FO. Oncogenic and non-oncogenic human genital papillomaviruses generate the E7 mRNA by different mechanisms. *J Virol* 1989; 63: 1441 – 1447.

Smotkin D, Wettstein FO. Transcription of human papillomavirus type 16 early genes in a cervical cancer and a cancer-derived cell line and identification of the E7 protein. *Proc Natl Acad Sci USA*. 1986; 24: 4680 – 4684.

Sotlar K, Selinka H-C, Menton M, Kandoff R, Bultmann B. Detection of human papillomavirus type 16 E6.E7 oncogene transcripts in dysplastic and non-dysplastic cervical scrapes by nested RT-PCR. *Gynecol Oncol*, 1998; 69: 114 – 121.

Southern SA, Herrington CS. Disruption of cell cycle control by human papillomaviruses with special reference to cervical carcinoma. *Int J Gynecol Cancer* 2000; 10: 263 – 274.

Southern SA, Herrington CS. Molecular events in uterine cervical cancer. *Sex Transm Inf* 1998; 74: 101 – 110.

Spinillo A, Tenti P, Zappatore R, et al. Langerhans cell-counts and cervical intraepithelial neoplasia in women with immunodeficiency virus infection. *Gynecol Oncol* 1993; 48: 210 – 213.

Spitzer M. Lower genital tract intraepithelial neoplasia in HIV-infected women: evaluation and management. *Obstet Gynecol Surv.* 1999; 54: 131 – 137.

Stanley MA. Human papillomavirus vaccines. *Rev Med Virol* 2006; 16: 139 – 149.

Stanley MA. Immune intervention in HPV infections: current progress and future developments. *Expert Rev Vaccines* 2003; 5: 615 – 617

Stanley MA. Immunobiology of HPV and HPV vaccines. *Gynecol Oncol* 2008; 109 (Suppl): S15-S21

Stanley MA. Immunobiology of papillomavirus infections. *J Reprod Immunol* 2001; 52: 45 – 59.

Stern E, Forsythe AB, Youkeles L, Coffelt CF. Steroid contraceptive use and cervical dysplasia: Increased risk of progression. *Science* 1977; 196: 1460 – 1462.

Stoler MH, Rhodes CR, Whitbeck A, Wolinsky SM, Chow LT, Broker TR. Human papillomavirus type 16 and 18 gene expression in cervical neoplasia. *Hum Pathol* 1992; 23: 117 – 128.

Strahle U, Klock G, Schutz G. A DNA sequence of 15 base pairs is sufficient to mediate both glucocorticoid and progesterone induction of gene expression. *Proc Natl Acad Sci USA* 1987; 84: 7871 – 7875.

Stunkel W, Huang Z, Tan SH, O'Connor M, Bernard HU. Nuclear matrix attachment regions of human papillomavirus 16 repress or activate the E6 promoter depending on the physical state of the viral DNA. *J Virol* 2000; 74: 2489 – 2501.

Sun XW, Kuhn L, Ellerbrock TV, et al. Human papillomavirus infection in women infected with the human immunodeficiency virus. *N Engl J Med* 1997; 337: 1343 – 1349.

Sun XW, Ellerbrock TV, Lungu O, Chiasson MA, Bush TJ, Wright TC. Human papillomavirus infection in human immunodeficiency virus-seropositive women. *Obstet Gynecol* 1995; 85: 680 - 686

Swan DC, Tucker RA, Tortolero-Luna G, et al. Human papillomavirus (HPV) DNA copy number is dependent on grade of cervical disease and HPV type. *J Clin Microbiol* 1999; 37: 1030 – 1034.

Syrjanen K. New concepts on risk factors of HPV and novel screening strategies for cervical cancer precursors. *Eur J Gynaecol Oncol* 2008; 29: 205 - 221

Syrjanen K, Shabalova I, Petrovichev N, Kozachencko V, Zakharova T, Pajanidi J, et al. Oral contraceptives are not an independent risk factor for cervical intraepithelial neoplasia or high-risk human infections. *Anticancer* 2006; 26: 4729 – 4740.

Szostek S, Klimek M, Zawilińska B, Kosz-Vnenchak M. Physical state of human papillomavirus type 16 in cervical cell DNA. *Folia Biol* 2008; 56: 269 – 271.

Talora C, Sgori DC, Crum CP, Dotto GP. Specific down-modulation of Notch 1 signalling in cervical cancer cells is required for sustained HPV-E6/E7 expression and late steps of malignant transformation. *Genes Dev* 2002; 16: 2252 – 2263.

Telang NT, Suto A, Wong GY, Osborne MP, Bradlow HL. Induction by estrogen metabolite 16 alphahydroxyestrone of genotoxic damage and aberrant proliferation in mouse mammary epithelial cells. *J Natl Cancer Inst* 1992; 84: 634 – 638.

Terris M & Oalman MC. Carcinoma of the cervix: An epidemiologic study. *JAMA* 1960; 174: 1847 – 1851.

Thomas DB, Qin Q, Kuypers J, Kiviat N, Ashley RL, Koetsawang A, Ray RM, Koetsawang S. Human papillomaviruses and cervical cancer in Bangkok. II. Risk factors for in situ and invasive squamous cell cervical carcinomas. *Am J Epidemiol* 2001; 153: 732 - 739

Thomas JT, Laimins LA, Ruesch MN. Perturbation of cell cycle control by E6 and E7 oncoproteins of human papillomaviruses. *Papillomavirus Rep* 1998; 9: 59 – 64.

Tong X and Howley PM. The bovine papillomavirus E6 oncoprotein interacts with paxillin and disrupts the actin cytoskeleton. *Proc Natl Acad Science USA* 1997; 94: 4412 – 4417.

Ustav E, Ustav M. E2 protein as the master regulator of extrachromosomal replication of the papillomaviruses. *Papillomavirus Rep* 1998; 9: 145 – 152

Vaccarella S, Herrero R, Dai M, Snijders PJ, Meijer CJ, Thomas JO, et al. Reproductive factors, oral contraceptive use and human papillomavirus infection: pooled analysis of the IARC HPV surveys. *Cancer Epidemiol Biomarkers Prev* 2006; 15: 2148 – 2153.

Van Eenwyk J, Davis FG, Bowen PE. Dietary and serum carotenoids and cervical intraepithelial neoplasia. *Int J Cancer* 1991; 1: 119 – 124.

Veljkovic M, Veljkovic S. The risk of breast cervical, endometrial and ovarian cancer in oral contraceptive users. *Med Prevl*, 2010;63: 657 – 661.

Vessey MP, Lawless M, McPherson K, Yeates D. Neoplasia of the cervix uteri and contraception: A possible adverse effect of the pill. *Lancet* 1983a; 2: 930 – 934.

Vessey MP, Lawless M, McPherson K, Yeates D. Oral contraceptives and cervical cancer (letter) *Lancet* 1983b; 2: 1358-1359

Vessey M, Painter R, Yeates D. Mortality in relation to oral contraceptive use and cigarette smoking. *Lancet* 2003; 362: 185 – 191.

Vessey M, Yeates D, Flynn S. Factors affecting mortality in a large cohort study with special reference to oral contraceptive use. *Contraception* 2010; 82: 221 – 229.

Villa LL, Costa RL, Petta CA, Andrade RP, Ault KA, Giuliano AR, et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16 and 18) L1 virus-like particle vaccine in young women: a randomized double-blind placebo-controlled multicentre phase II efficacy trial. *Lancet Oncol* 2005; 6: 271 – 278.

Vogelstein B, Lane D, Levine AJ. Surfing the p53 network. *Nature* 2000; 408: 307 – 310.

Vonka V, Kanka J, Hirsch I, Zavadova H et al. Prospective study on the relationship between cervical neoplasia and herpes simplex type – 2 virus. Herpes simplex type 2 antibody presence in sera at enrolment. *Int J Cancer* 1984; 33: 61 – 66.

von Knebel Doeberitz M, Bankrecht T, Bartsch D and zur Hausen H. Influence of chromosomal integration on glucocorticoid-regulated transcription of growth stimulating papillomavirus genes E6 and E7 in cervical carcinoma cells. *Proc Natl Acad Sci USA* 1991; 88: 1411 – 1415.

Von Knebel Doeberitz M. Dexamethasone-enhanced cisplatin resistance of human lung carcinoma cells. *Contrib Oncol* 1997; 49: 81 - 87

Von Knebel Doeberitz M, Rittmuller C, Aengeneyndt F, Jensen Durr P, Spitkovsky D. Reversible repression of papillomavirus oncogene expression in cervical carcinoma cells: consequence for phenotypes and E6-*p53* and E2-*pRB* interactions. *J Virol* 1994; 68: 2811 – 2821.

Wani K, Nair CK. Genetic alterations in cervical cancer. *Indian J Exp Biol* 2003; 41: 789 – 796.

Wank R, Thomssen C. High-risk squamous cell carcinomas of the cervix for women with HLA-DQw3. *Nature* 1991; 352: 723 – 725.

Wang Y, Liu VW, Tsang PC, et al. Microsatellite instability in mitochondrial genome of common female cancers 2006; 16: 259 – 266.

Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, Snijders PJ, Peto J, Meijer CJ, Munoz N. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. *J Pathol* 1999; 189: 12 – 19.

Webb D. The HIV/AIDS epidemic in Southern Africa. In: Webb D ed. *HIV and AIDS in Africa*. Pluto Press. 1997; 1 – 28.

Weinberg R. The retinoblastoma protein and cell cycle control. *Cell* 1995; 81: 323 – 330.

Wellensiek N, Moodley M, Moodley J. Knowledge of cervical cancer screening and use of cervical screening facilities amongst women from various socioeconomic backgrounds in Durban, Kwazulu Natal, South Africa. *Int J Gynecol Cancer* 2002; 12: 376 - 382

Wilczynski SP, Bergen S, Walker J. Human papillomaviruses and cervical cancer. Analysis of histopathologic features associated with different viral types. *Human Pathol* 1988; 19: 697 – 704.

Wilson VG, West M, Woytek K, et al. Papillomavirus E1 proteins: form, function and features. *Virus Genes* 2002; 24: 275 - 290

Woodman CB, Collins SI, Young LS. The natural history of cervical HPV infection: unresolved issues. *Nat Rev Cancer* 2007; 7: 11 – 22.

Womack SD, Chirenje ZM, Blumenthal PD et al. Evaluation of a human papillomavirus assay in cervical screening in Zimbabwe. *Br J Obstet Gynaecol* 2000; 107: 33 – 38.

Wong YF, Cheung TH, Poon, et al. The role of microsatellite instability in cervical intraepithelial neoplasia and squamous cell carcinoma of the cervix. *Gynecol Oncol* 2003; 89: 434 – 439.

World Health Organization. Depot-medroxyprogesterone acetate (DMPA) and cancer: memorandum from a WHO meeting. *Bull World Health Organ* 1993; 71: 669-676

World Health organization Collaboration Study of Neoplasia and Steroid contraceptives, invasive squamous cell carcinomas and combined oral contraceptives. *Br Med J* 1985; 290: 961 - 965

Worth AJ, Boyes DA: A case-control study into the possible effects of birth control pills on pre-clinical carcinoma of the cervix. *J Obstet Gynaecol Br Commonw* 1972; 79: 673-679

Xu W-H, Xiang Y-B, Ruan Z-X. Menstrual and reproductive factors and endometrial cancer risk: results from a population-based case-control study in urban Shanghai. *Int J Cancer* 2004; 108: 613 – 619.

Yang X, Jin G, Nakao Y, Rahimtula M, Pater MM, Pater A. Malignant transformation of HPV 16 immortalized human endocervical cells by cigarette smoke condensate and characterization of multistage carcinogenesis. *Int J Cancer* 1996; 65: 338 – 344.

Ylitalo N, Sorensen P, Josefsson A, et al. Smoking and oral contraceptives as risk factors for cervical carcinoma in-situ. *Int J Cancer* 1999; 81: 357 – 365.

Yuan F, Auburn K, James C. Altered growth and viral gene expression in human papillomavirus type 16-containing cancer cell lines treated with progesterone. *Cancer Invest* 1999; 17: 19 – 29.

Yugawa T, Handa K, Narisawa-Saito M, Ohno S, Fujita M, Kiyono T. Regulation of Notch 1 gene expression by p53 in epithelial cells. *Mol Cell Biol* 2007; 27: 3732 – 3742.

Zagouras P, Stifani S, Blaumueller CM, Carcangiu ML, Artvanis-Tsakonas S. Alterations in Notch signaling in neoplastic lesions of the human cervix. *Proc Natl Acad Sci USA* 1995; 92: 6414 – 6418.

Zheng ZM, Baker CC. Papillomavirus genome structure, expression, and post-transcriptional regulation. *Front Biosci* 2006; 11: 2286 – 2302.

Zhou J, Crawford L, McLean L, Sun XY, Stanley MA, Almond N, Smith GL. Increased antibody responses to human papillomavirus type 16 L1 protein expressed by recombinant vaccinia virus lacking serine protease inhibitor genes. *J Gen Virol* 1990; 71: 2185 – 2190.

Zobel T, Iftner T, Stubenrauch F. The papillomavirus E8-E2C protein repress DNA replication from extrachromosomal origins. *Molecular Cellular Biology* 2003; 23: 8352 – 8362.

Zondervan KT, Carpenter LM, Painter R, et al. Oral contraceptives and cervical cancer- further findings from the Oxford Family Planning Association contraceptive study. *Br J Cancer* 1996; 73: 1291 – 1297.

zur Hausen H. Human genital cancer: Synergism between two viral infections or synergism between a virus and initiating events? *Lancet* 1982; 2: 1370 – 1372.

zur Hausen H. Papillomaviruses causing cancer: evasion from host-cell control in early events in carcinogenesis. *J Natl Cancer Inst* 2000; 92: 690 - 698

zur Hausen H. Papillomaviruses in human cancers. *Molecular Carcinogenesis* 1988; 1: 147 – 150.

Zwerschke W, Mannhardt B, Weinzimer S et al. The human papillomavirus E7 oncoprotein binds and inactivates the growth inhibitory IGF-binding protein-3. In: 18th International PV Conference, 2000, pp368, Castellsagne X, Bosch FX, de Sanjose S et al, eds. Thau, SL. Barcelona.